cid,cmpdname,cmpdsynonym,mw,mf,polararea,complexity,xlogp,heavycnt,hbonddonor,hbondacc,rotbonds,inchi,isosmiles,canonicalsmiles,inchikey,iupacname,exactmass,monoisotopicmass,charge,covalentunitcnt,isotopeatomcnt,totalatomstereocnt,definedatomstereocnt,undefinedatomstereocnt,totalbondstereocnt,definedbondstereocnt,undefinedbondstereocnt,pclidcnt,gpidcnt,gpfamilycnt,meshheadings,annothits,annothitcnt,aids,cidcdate,sidsrcname,depcatg,annotation
 164517053,KRAS G12C inhibitor 54,KRAS G12C inhibitor 54|HY-147635,707.800,C36H40F3N7O3S,125.000,1380.000,7.300,50,1,11,7,"InChI=1S/C36H40F3N7O3S/c1-3-28(47)46-19-35(20-46)11-13-45(14-12-35)33-25-17-24(23-8-9-23)30(29-22(2)7-10-27-26(29)18-40-43-27)32(49-21-36(37,38)39)31(25)41-34(42-33)44-50(48)15-5-4-6-16-50/h3,7,10,17-18,23H,1,4-6,8-9,11-16,19-21H2,2H3,(H,40,43)",CC1=C(C2=C(C=C1)NN=C2)C3=C(C=C4C(=C3OCC(F)(F)F)N=C(N=C4N5CCC6(CC5)CN(C6)C(=O)C=C)N=S7(=O)CCCCC7)C8CC8,CC1=C(C2=C(C=C1)NN=C2)C3=C(C=C4C(=C3OCC(F)(F)F)N=C(N=C4N5CCC6(CC5)CN(C6)C(=O)C=C)N=S7(=O)CCCCC7)C8CC8,MOWSGIAREXMCDJ-UHFFFAOYSA-N,"1-[7-[6-cyclopropyl-7-(5-methyl-1H-indazol-4-yl)-2-[(1-oxothian-1-ylidene)amino]-8-(2,2,2-trifluoroethoxy)quinazolin-4-yl]-2,7-diazaspiro[3.5]nonan-2-yl]prop-2-en-1-one",707.287,707.287,0,1,0,0,0,0,0,0,0,0,0,0,"",Classification|Patents,2,"",20220727,MedChemexpress MCE|PATENTSCOPE (WIPO),Chemical Vendors|Governmental Organizations,""
164173905,KRAS G12C inhibitor 49,"KRAS G12C inhibitor 49|2761380-32-7|SCHEMBL25532675|DA-64777|HY-147630|2-[6-chloro-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]-2-oxopyrido[2,3-d]pyrimidin-7-yl]benzaldehyde",571.100,C31H31ClN6O3,99.100,1040.000,4.200,41,0,5,6,"InChI=1S/C31H31ClN6O3/c1-6-25(40)36-13-14-37(20(5)16-36)29-23-15-24(32)27(22-10-8-7-9-21(22)17-39)34-30(23)38(31(41)35-29)28-19(4)11-12-33-26(28)18(2)3/h6-12,15,17-18,20H,1,13-14,16H2,2-5H3/t20-/m0/s1",C[C@H]1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)Cl)C4=CC=CC=C4C=O)C5=C(C=CN=C5C(C)C)C)C(=O)C=C,CC1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)Cl)C4=CC=CC=C4C=O)C5=C(C=CN=C5C(C)C)C)C(=O)C=C,ZXUJCJOXPIRART-FQEVSTJZSA-N,"2-[6-chloro-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]-2-oxopyrido[2,3-d]pyrimidin-7-yl]benzaldehyde",570.215,570.215,0,1,0,1,1,0,0,0,0,0,1,1,"",Patents,1,"",20220706,"Debye Scientific Co., Ltd|Google Patents|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
163409094,KRAS G12C inhibitor 48,"KRAS G12C inhibitor 48|HY-146061|CS-0498800|(E)-2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carbonyl)-3-cyclopropylacrylonitrile",651.200,C36H39ClN8O2,113.000,1260.000,5.400,47,0,9,8,"InChI=1S/C36H39ClN8O2/c1-42-15-4-7-28(42)23-47-36-40-31-22-43(32-9-3-6-25-5-2-8-30(37)33(25)32)16-13-29(31)34(41-36)44-17-18-45(27(21-44)12-14-38)35(46)26(20-39)19-24-10-11-24/h2-3,5-6,8-9,19,24,27-28H,4,7,10-13,15-18,21-23H2,1H3/b26-19+/t27-,28-/m0/s1",CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)/C(=C/C7CC7)/C#N,CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=CC7CC7)C#N,CROGWWKTKKFIJR-YUWSGBISSA-N,"(E)-2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carbonyl]-3-cyclopropylprop-2-enenitrile",650.288,650.288,0,1,0,2,2,0,1,1,0,0,0,0,"",Patents,1,"",20220630,AbaChemScene|BLD Pharm|MedChemexpress MCE|PATENTSCOPE (WIPO)|TargetMol,Chemical Vendors|Governmental Organizations,""
163408777,KRAS G12C inhibitor 43,"KRAS G12C inhibitor 43|2648808-69-7|SCHEMBL23632581|HY-142945|CS-0373983|2-[(2S)-4-[7-(3-methoxynaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]pyrido[2,3-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",577.700,C33H35N7O3,108.000,1020.000,4.700,43,0,9,8,"InChI=1S/C33H35N7O3/c1-4-30(41)40-17-16-39(20-23(40)13-14-34)32-27-11-12-29(28-19-25(42-3)18-22-8-5-6-10-26(22)28)35-31(27)36-33(37-32)43-21-24-9-7-15-38(24)2/h4-6,8,10-12,18-19,23-24H,1,7,9,13,15-17,20-21H2,2-3H3/t23-,24-/m0/s1",CN1CCC[C@H]1COC2=NC3=C(C=CC(=N3)C4=CC(=CC5=CC=CC=C54)OC)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C=C,CN1CCCC1COC2=NC3=C(C=CC(=N3)C4=CC(=CC5=CC=CC=C54)OC)C(=N2)N6CCN(C(C6)CC#N)C(=O)C=C,JXYVRMVMAUIZEY-ZEQRLZLVSA-N,"2-[(2S)-4-[7-(3-methoxynaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]pyrido[2,3-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",577.28,577.28,0,1,0,2,2,0,0,0,0,0,1,1,"",Patents,1,"",20220630,AbaChemScene|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol,Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
163206602,KRAS G12C inhibitor 50,"KRAS G12C inhibitor 50|2760354-12-7|SCHEMBL26124166|BDBM625377|US20230322788, Compound A4|HY-147631|2-[(2S)-4-[2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-7-(naphthalen-1-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",550.700,C31H34N8O2,103.000,971.000,3.900,41,0,8,8,"InChI=1S/C31H34N8O2/c1-3-28(40)38-17-16-37(20-24(38)13-14-32)30-29-33-19-26(18-23-10-6-9-22-8-4-5-12-27(22)23)39(29)35-31(34-30)41-21-25-11-7-15-36(25)2/h3-6,8-10,12,19,24-25H,1,7,11,13,15-18,20-21H2,2H3/t24-,25-/m0/s1",CN1CCC[C@H]1COC2=NN3C(=CN=C3C(=N2)N4CCN([C@H](C4)CC#N)C(=O)C=C)CC5=CC=CC6=CC=CC=C65,CN1CCCC1COC2=NN3C(=CN=C3C(=N2)N4CCN(C(C4)CC#N)C(=O)C=C)CC5=CC=CC6=CC=CC=C65,OMJLVKOHXNQCJC-DQEYMECFSA-N,"2-[(2S)-4-[2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-7-(naphthalen-1-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",550.28,550.28,0,1,0,2,2,0,0,0,0,0,1,1,"",Biological Test Results|Patents|Biological Test Results: Active|Biological Test Results: Micromolar,4,1919853,20220513,BindingDB|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol,Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
163196256,KRAS G12C inhibitor 34,"KRAS G12C inhibitor 34|2749948-26-1|SCHEMBL24070494|DA-54671|HY-142511|CS-0372560|(4aR)-7-chloro-8-(5-methyl-1H-indazol-4-yl)-10-(2-propan-2-ylanilino)-3-prop-2-enoyl-2,4,4a,5-tetrahydro-1H-pyrazino[2,1-c][1,4]benzoxazepin-11-one",570.100,C32H32ClN5O3,90.600,981.000,6.500,41,2,5,5,"InChI=1S/C32H32ClN5O3/c1-5-27(39)37-12-13-38-20(16-37)17-41-31-29(32(38)40)26(35-24-9-7-6-8-21(24)18(2)3)14-22(30(31)33)28-19(4)10-11-25-23(28)15-34-36-25/h5-11,14-15,18,20,35H,1,12-13,16-17H2,2-4H3,(H,34,36)/t20-/m1/s1",CC1=C(C2=C(C=C1)NN=C2)C3=CC(=C4C(=C3Cl)OC[C@H]5CN(CCN5C4=O)C(=O)C=C)NC6=CC=CC=C6C(C)C,CC1=C(C2=C(C=C1)NN=C2)C3=CC(=C4C(=C3Cl)OCC5CN(CCN5C4=O)C(=O)C=C)NC6=CC=CC=C6C(C)C,SPPFMHRDAZXATL-HXUWFJFHSA-N,"(4aR)-7-chloro-8-(5-methyl-1H-indazol-4-yl)-10-(2-propan-2-ylanilino)-3-prop-2-enoyl-2,4,4a,5-tetrahydro-1H-pyrazino[2,1-c][1,4]benzoxazepin-11-one",569.219,569.219,0,1,0,1,1,0,0,0,0,0,1,1,"",Patents,1,"",20220428,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
163196255,KRAS G12C inhibitor 32,KRAS G12C inhibitor 32|2756739-00-9|SCHEMBL24161933|HY-142487|CS-0372523,635.900,C29H30Cl3FN6O3,83.100,966.000,6.100,42,1,9,5,"InChI=1S/C29H30Cl3FN6O3/c1-3-21(40)38-8-10-39(11-9-38)28-17-13-18(30)22-23-24(33)19(31)14-20(32)26(23)34-6-12-41-27(22)25(17)35-29(36-28)42-15-16-5-4-7-37(16)2/h3,13-14,16,34H,1,4-12,15H2,2H3/t16-/m0/s1",CN1CCC[C@H]1COC2=NC3=C4C(=C(C=C3C(=N2)N5CCN(CC5)C(=O)C=C)Cl)C6=C(C(=CC(=C6F)Cl)Cl)NCCO4,CN1CCCC1COC2=NC3=C4C(=C(C=C3C(=N2)N5CCN(CC5)C(=O)C=C)Cl)C6=C(C(=CC(=C6F)Cl)Cl)NCCO4,ZQYOQPIFEDBQMJ-INIZCTEOSA-N,"1-[4-[4,6,20-trichloro-3-fluoro-15-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-11-oxa-8,14,16-triazatetracyclo[10.8.0.02,7.013,18]icosa-1(20),2(7),3,5,12,14,16,18-octaen-17-yl]piperazin-1-yl]prop-2-en-1-one",634.143,634.143,0,1,0,1,1,0,0,0,0,0,1,1,"",Classification|Patents,2,"",20220428,AbaChemScene|BLD Pharm|Google Patents|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol,Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
163196254,KRAS G12C inhibitor 31,KRAS G12C inhibitor 31|2752352-86-4|DA-74792|HY-142485|CS-0372487,508.900,C25H22ClFN6O3,90.800,886.000,3.600,36,1,6,5,"InChI=1S/C25H22ClFN6O3/c1-3-20(34)28-15-8-10-16(11-9-15)31-12-5-13-32-21-22(29-24(31)32)30(2)25(36)33(23(21)35)14-17-18(26)6-4-7-19(17)27/h3-4,6-11H,1,5,12-14H2,2H3,(H,28,34)",CN1C2=C(C(=O)N(C1=O)CC3=C(C=CC=C3Cl)F)N4CCCN(C4=N2)C5=CC=C(C=C5)NC(=O)C=C,CN1C2=C(C(=O)N(C1=O)CC3=C(C=CC=C3Cl)F)N4CCCN(C4=N2)C5=CC=C(C=C5)NC(=O)C=C,VXJGLDRLVRUPIS-UHFFFAOYSA-N,"N-[4-[3-[(2-chloro-6-fluorophenyl)methyl]-1-methyl-2,4-dioxo-7,8-dihydro-6H-purino[7,8-a]pyrimidin-9-yl]phenyl]prop-2-enamide",508.143,508.143,0,1,0,0,0,0,0,0,0,0,0,0,"",Classification,1,"",20220428,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|MedChemexpress MCE|TargetMol",Chemical Vendors,""
163196253,KRAS G12C inhibitor 30,KRAS G12C inhibitor 30|2752352-90-0|DA-54670|HY-142481|CS-0372482,508.900,C25H22ClFN6O3,90.800,894.000,3.600,36,1,6,5,"InChI=1S/C25H22ClFN6O3/c1-3-20(34)28-15-7-4-8-16(13-15)31-11-6-12-32-21-22(29-24(31)32)30(2)25(36)33(23(21)35)14-17-18(26)9-5-10-19(17)27/h3-5,7-10,13H,1,6,11-12,14H2,2H3,(H,28,34)",CN1C2=C(C(=O)N(C1=O)CC3=C(C=CC=C3Cl)F)N4CCCN(C4=N2)C5=CC=CC(=C5)NC(=O)C=C,CN1C2=C(C(=O)N(C1=O)CC3=C(C=CC=C3Cl)F)N4CCCN(C4=N2)C5=CC=CC(=C5)NC(=O)C=C,FYTIAUJXQNHTOR-UHFFFAOYSA-N,"N-[3-[3-[(2-chloro-6-fluorophenyl)methyl]-1-methyl-2,4-dioxo-7,8-dihydro-6H-purino[7,8-a]pyrimidin-9-yl]phenyl]prop-2-enamide",508.143,508.143,0,1,0,0,0,0,0,0,0,0,0,0,"",Classification,1,"",20220428,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|InvivoChem|MedChemexpress MCE|TargetMol",Chemical Vendors,""
162732889,KRAS G12C inhibitor 53,KRAS G12C inhibitor 53|HY-147634|2761968-93-6,441.800,C21H14ClF2N5O2,84.100,713.000,3.300,31,1,7,3,"InChI=1S/C21H14ClF2N5O2/c1-2-16(31)28-8-10(9-28)29-21-11-6-12(22)17(18-13(23)4-3-5-15(18)30)19(24)20(11)25-7-14(21)26-27-29/h2-7,10,30H,1,8-9H2",C=CC(=O)N1CC(C1)N2C3=C(C=NC4=C(C(=C(C=C43)Cl)C5=C(C=CC=C5F)O)F)N=N2,C=CC(=O)N1CC(C1)N2C3=C(C=NC4=C(C(=C(C=C43)Cl)C5=C(C=CC=C5F)O)F)N=N2,FLWRXXXGEGVGBY-UHFFFAOYSA-N,"1-[3-[8-chloro-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)triazolo[4,5-c]quinolin-1-yl]azetidin-1-yl]prop-2-en-1-one",441.08,441.08,0,1,0,0,0,0,0,0,0,0,0,0,"",Classification|Patents,2,"",20220405,MedChemexpress MCE|PATENTSCOPE (WIPO)|TargetMol,Chemical Vendors|Governmental Organizations,""
162732836,KRAS G12C inhibitor 52,KRAS G12C inhibitor 52|SCHEMBL25412792|HY-147633,670.700,C34H32F2N8O3S,157.000,1370.000,4.300,48,1,11,4,"InChI=1S/C34H32F2N8O3S/c1-7-23(45)42-14-22-32(46)41(6)29-28(43(22)13-17(42)5)19-12-21(36)25(18-8-9-20(35)30-26(18)40-34(37)48-30)39-31(19)44(33(29)47)27-16(4)10-11-38-24(27)15(2)3/h7-12,15,17,22H,1,13-14H2,2-6H3,(H2,37,40)/t17-,22-/m1/s1",C[C@@H]1CN2[C@H](CN1C(=O)C=C)C(=O)N(C3=C2C4=CC(=C(N=C4N(C3=O)C5=C(C=CN=C5C(C)C)C)C6=C7C(=C(C=C6)F)SC(=N7)N)F)C,CC1CN2C(CN1C(=O)C=C)C(=O)N(C3=C2C4=CC(=C(N=C4N(C3=O)C5=C(C=CN=C5C(C)C)C)C6=C7C(=C(C=C6)F)SC(=N7)N)F)C,BVZBQFKRIRKRES-VGOFRKELSA-N,"(4R,7R)-15-(2-amino-7-fluoro-1,3-benzothiazol-4-yl)-16-fluoro-4,9-dimethyl-12-(4-methyl-2-propan-2-ylpyridin-3-yl)-5-prop-2-enoyl-2,5,9,12,14-pentazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),13,15,17-tetraene-8,11-dione",670.229,670.229,0,1,0,2,2,0,0,0,0,0,0,0,"",Classification|Patents,2,"",20220405,MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL,Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
162732743,KRAS G12C inhibitor 51,"KRAS G12C inhibitor 51|2762632-78-8|DA-54675|HY-147632|6-cyclopropyl-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one",582.700,C33H35FN6O3,102.000,1100.000,4.800,43,1,6,6,"InChI=1S/C33H35FN6O3/c1-6-26(42)38-14-15-39(20(5)17-38)31-23-16-22(21-10-11-21)29(27-24(34)8-7-9-25(27)41)36-32(23)40(33(43)37-31)30-19(4)12-13-35-28(30)18(2)3/h6-9,12-13,16,18,20-21,41H,1,10-11,14-15,17H2,2-5H3/t20-/m0/s1",C[C@H]1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)C4CC4)C5=C(C=CC=C5F)O)C6=C(C=CN=C6C(C)C)C)C(=O)C=C,CC1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)C4CC4)C5=C(C=CC=C5F)O)C6=C(C=CN=C6C(C)C)C)C(=O)C=C,ITSNQKZLCHHZEF-FQEVSTJZSA-N,"6-cyclopropyl-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one",582.275,582.275,0,1,0,1,1,0,0,0,0,0,0,0,"",Classification|Patents,2,"",20220405,"Debye Scientific Co., Ltd|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|TargetMol",Chemical Vendors|Governmental Organizations,""
162679270,KRAS G12C inhibitor 23,"KRAS G12C inhibitor 23|2735721-00-1|SCHEMBL25679057|DA-54665|HY-145020|CS-0312209|11-fluoro-4-(4-methyl-2-propan-2-ylpyridin-3-yl)-1-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]-6H-isochromeno[4,3-h]quinazolin-3-one",553.600,C32H32FN5O3,78.300,1050.000,4.500,41,0,5,4,"InChI=1S/C32H32FN5O3/c1-6-25(39)36-13-14-37(20(5)16-36)31-23-15-24(33)26-22-10-8-7-9-21(22)17-41-30(26)29(23)38(32(40)35-31)28-19(4)11-12-34-27(28)18(2)3/h6-12,15,18,20H,1,13-14,16-17H2,2-5H3/t20-/m0/s1",C[C@H]1CN(CCN1C2=NC(=O)N(C3=C4C(=C(C=C32)F)C5=CC=CC=C5CO4)C6=C(C=CN=C6C(C)C)C)C(=O)C=C,CC1CN(CCN1C2=NC(=O)N(C3=C4C(=C(C=C32)F)C5=CC=CC=C5CO4)C6=C(C=CN=C6C(C)C)C)C(=O)C=C,UWIDMHGDYVIUOQ-FQEVSTJZSA-N,"11-fluoro-4-(4-methyl-2-propan-2-ylpyridin-3-yl)-1-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]-6H-isochromeno[4,3-h]quinazolin-3-one",553.249,553.249,0,1,0,1,1,0,0,0,0,0,0,0,"",Classification|Patents,2,"",20220329,"AbaChemScene|BLD Pharm|BOC Sciences|Debye Scientific Co., Ltd|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
162494732,KRAS G12C inhibitor 56,KRAS G12C inhibitor 56|SCHEMBL24091826|HY-148261|CS-0617473|2749963-77-5,617.800,C32H39N7O4S,172.000,1080.000,5.300,44,1,11,8,"InChI=1S/C32H39N7O4S/c1-5-28(40)39-14-10-20(11-15-39)42-27-17-26(41-19(2)22-8-7-13-38(22)4)35-31(36-27)23-16-25(37-43-23)32(3)12-6-9-24-29(32)21(18-33)30(34)44-24/h5,16-17,19-20,22H,1,6-15,34H2,2-4H3/t19-,22-,32+/m0/s1",C[C@@H]([C@@H]1CCCN1C)OC2=NC(=NC(=C2)OC3CCN(CC3)C(=O)C=C)C4=CC(=NO4)[C@]5(CCCC6=C5C(=C(S6)N)C#N)C,CC(C1CCCN1C)OC2=NC(=NC(=C2)OC3CCN(CC3)C(=O)C=C)C4=CC(=NO4)C5(CCCC6=C5C(=C(S6)N)C#N)C,VPGFGUVVEBRZJS-RKGKDDSLSA-N,"(4S)-2-amino-4-methyl-4-[5-[4-[(1S)-1-[(2S)-1-methylpyrrolidin-2-yl]ethoxy]-6-(1-prop-2-enoylpiperidin-4-yl)oxypyrimidin-2-yl]-1,2-oxazol-3-yl]-6,7-dihydro-5H-1-benzothiophene-3-carbonitrile",617.278,617.278,0,1,0,3,3,0,0,0,0,0,1,1,"",Patents,1,"",20220206,AbaChemScene|Google Patents|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol,Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
159448580,KRAS G12C inhibitor 44,KRAS G12C inhibitor 44|2927439-07-2|SCHEMBL23645261|HY-142946|CS-0373987,579.100,C31H36ClFN6O2,85.600,1040.000,5.300,41,0,8,6,"InChI=1S/C31H36ClFN6O2/c1-20(33)29(40)39-16-15-38(18-21(39)10-13-34)28-24-9-12-31(11-8-23-25(31)6-3-7-26(23)32)17-27(24)35-30(36-28)41-19-22-5-4-14-37(22)2/h3,6-7,21-22H,1,4-5,8-12,14-19H2,2H3/t21-,22-,31-/m0/s1",CN1CCC[C@H]1COC2=NC3=C(CC[C@]4(C3)CCC5=C4C=CC=C5Cl)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C(=C)F,CN1CCCC1COC2=NC3=C(CCC4(C3)CCC5=C4C=CC=C5Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=C)F,LTBOVTGFAXPDLV-CYYCZYJVSA-N,"2-[(2S)-4-[(3R)-7-chloro-2'-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]spiro[1,2-dihydroindene-3,7'-6,8-dihydro-5H-quinazoline]-4'-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile",578.257,578.257,0,1,0,3,3,0,0,0,0,0,3,1,"",Classification|Patents,2,"",20211203,AbaChemScene|BLD Pharm|Google Patents|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol,Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
157827766,Glecirasib,Glecirasib|KRAS G12C inhibitor 36|KRAS G12C inhibitor 62|2657613-87-9|2658588-10-2|glecirasib [INN]|UP75WH4QKM|CHEMBL5314518|SCHEMBL23830094|EX-A8185Q|DA-54672|HY-143589|HY-157067|CS-0373885|CS-0904896|2658538-04-4,640.000,C31H26ClF4N7O2,119.000,1240.000,4.400,45,1,11,5,"InChI=1S/C31H26ClF4N7O2/c1-5-19(44)41-8-10-42(11-9-41)29-16-12-18(32)27(20-21(33)22(34)23(35)24(36)25(20)38)40-30(16)43(31(45)17(29)13-37)28-15(4)6-7-39-26(28)14(2)3/h5-7,12,14H,1,8-11,38H2,2-4H3",CC1=C(C(=NC=C1)C(C)C)N2C3=NC(=C(C=C3C(=C(C2=O)C#N)N4CCN(CC4)C(=O)C=C)Cl)C5=C(C(=C(C(=C5F)F)F)F)N,CC1=C(C(=NC=C1)C(C)C)N2C3=NC(=C(C=C3C(=C(C2=O)C#N)N4CCN(CC4)C(=O)C=C)Cl)C5=C(C(=C(C(=C5F)F)F)F)N,QRRJEUIQLZNPIO-UHFFFAOYSA-N,"7-(2-amino-3,4,5,6-tetrafluorophenyl)-6-chloro-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxo-4-(4-prop-2-enoylpiperazin-1-yl)-1,8-naphthyridine-3-carbonitrile",639.177,639.177,0,1,0,0,0,0,0,0,0,0,3,1,"",Classification|Drug and Medication Information|Patents|Associated Disorders and Diseases,4,"",20211203,"AbaChemScene|BLD Pharm|ChEMBL|Debye Scientific Co., Ltd|Excenen Pharmatech|FDA Global Substance Registration System (GSRS)|Google Patents|MedChemexpress MCE|MolGenie|MolPort|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
157023643,KRAS G12C inhibitor 21,KRAS G12C inhibitor 21|2737269-61-1|DA-74789|HY-145018|CS-0312207,580.100,C34H30ClN3O4,81.200,1050.000,6.800,42,1,4,6,"InChI=1S/C34H30ClN3O4/c1-4-32(40)36-17-21(18-36)19-37-30-16-28(35)27(26-14-23(39)13-22-9-5-6-11-25(22)26)15-31(30)38(34(42)33(37)41)29-12-8-7-10-24(29)20(2)3/h4-16,20-21,39H,1,17-19H2,2-3H3",CC(C)C1=CC=CC=C1N2C3=C(C=C(C(=C3)C4=CC(=CC5=CC=CC=C54)O)Cl)N(C(=O)C2=O)CC6CN(C6)C(=O)C=C,CC(C)C1=CC=CC=C1N2C3=C(C=C(C(=C3)C4=CC(=CC5=CC=CC=C54)O)Cl)N(C(=O)C2=O)CC6CN(C6)C(=O)C=C,RGGFDCIDHSJZIS-UHFFFAOYSA-N,"6-chloro-7-(3-hydroxynaphthalen-1-yl)-1-(2-propan-2-ylphenyl)-4-[(1-prop-2-enoylazetidin-3-yl)methyl]quinoxaline-2,3-dione",579.192,579.192,0,1,0,0,0,0,0,0,0,0,0,0,"",Patents,1,"",20211130,"AbaChemScene|BLD Pharm|BOC Sciences|Debye Scientific Co., Ltd|MedChemexpress MCE|PATENTSCOPE (WIPO)|TargetMol",Chemical Vendors|Governmental Organizations,""
157023450,KRAS G12C inhibitor 22,"KRAS G12C inhibitor 22|2736599-72-5|DA-64770|HY-145019|CS-0312208|2-[(2S)-4-[2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-7-(5,6,7,8-tetrahydronaphthalen-1-yl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",555.700,C32H41N7O2,88.800,969.000,4.200,41,0,8,7,"InChI=1S/C32H41N7O2/c1-3-30(40)39-19-18-38(20-24(39)13-15-33)31-27-14-17-37(29-12-6-9-23-8-4-5-11-26(23)29)21-28(27)34-32(35-31)41-22-25-10-7-16-36(25)2/h3,6,9,12,24-25H,1,4-5,7-8,10-11,13-14,16-22H2,2H3/t24-,25-/m0/s1",CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4CCCC5)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C=C,CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4CCCC5)C(=N2)N6CCN(C(C6)CC#N)C(=O)C=C,KTRZIDXGTRBXAH-DQEYMECFSA-N,"2-[(2S)-4-[2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-7-(5,6,7,8-tetrahydronaphthalen-1-yl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",555.332,555.332,0,1,0,2,2,0,0,0,0,0,0,0,"",Patents,1,"",20211130,"AbaChemScene|BLD Pharm|BOC Sciences|Debye Scientific Co., Ltd|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|TargetMol",Chemical Vendors|Governmental Organizations,""
157023122,KRAS G12C inhibitor 24,"KRAS G12C inhibitor 24|2735742-75-1|SCHEMBL23986308|DA-64771|HY-145021|CS-0312211|1-[4-[7-(2-amino-7-fluoro-1,3-benzothiazol-4-yl)-6-chloro-8-fluoro-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one",600.100,C28H28ClF2N7O2S,129.000,951.000,5.300,41,1,11,6,"InChI=1S/C28H28ClF2N7O2S/c1-3-20(39)37-9-11-38(12-10-37)26-17-13-18(29)21(16-6-7-19(30)25-24(16)33-27(32)41-25)22(31)23(17)34-28(35-26)40-14-15-5-4-8-36(15)2/h3,6-7,13,15H,1,4-5,8-12,14H2,2H3,(H2,32,33)/t15-/m0/s1",CN1CCC[C@H]1COC2=NC3=C(C(=C(C=C3C(=N2)N4CCN(CC4)C(=O)C=C)Cl)C5=C6C(=C(C=C5)F)SC(=N6)N)F,CN1CCCC1COC2=NC3=C(C(=C(C=C3C(=N2)N4CCN(CC4)C(=O)C=C)Cl)C5=C6C(=C(C=C5)F)SC(=N6)N)F,CDTUKBVALQMBRD-HNNXBMFYSA-N,"1-[4-[7-(2-amino-7-fluoro-1,3-benzothiazol-4-yl)-6-chloro-8-fluoro-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one",599.168,599.168,0,1,0,1,1,0,0,0,0,0,1,1,"",Classification|Patents,2,"",20211130,"AbaChemScene|BLD Pharm|BOC Sciences|Debye Scientific Co., Ltd|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
156898354,KRAS G12C inhibitor 25,KRAS G12C inhibitor 25|2734060-73-0|SCHEMBL23931956|DA-54666|HY-145022|CS-0312217,555.700,C32H41N7O2,88.800,969.000,4.100,41,0,8,7,"InChI=1S/C32H41N7O2/c1-3-30(40)39-19-18-37(21-25(39)14-15-33)31-27-13-12-24(38-17-6-9-23-8-4-5-11-29(23)38)20-28(27)34-32(35-31)41-22-26-10-7-16-36(26)2/h3-5,8,11,24-26H,1,6-7,9-10,12-14,16-22H2,2H3/t24-,25+,26+/m1/s1",CN1CCC[C@H]1COC2=NC3=C(CC[C@H](C3)N4CCCC5=CC=CC=C54)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C=C,CN1CCCC1COC2=NC3=C(CCC(C3)N4CCCC5=CC=CC=C54)C(=N2)N6CCN(C(C6)CC#N)C(=O)C=C,BVNQVRSIVGNVET-ZNZIZOMTSA-N,"2-[(2S)-4-[(7R)-7-(3,4-dihydro-2H-quinolin-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydroquinazolin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",555.332,555.332,0,1,0,3,3,0,0,0,0,0,1,1,"",Patents,1,"",20211110,"AbaChemScene|BLD Pharm|BOC Sciences|Debye Scientific Co., Ltd|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
156805856,KRAS G12C inhibitor 45,"KRAS G12C inhibitor 45|2670380-74-0|SCHEMBL24108720|DA-54674|HY-142947|CS-0374000|4-[(2S,5R)-2,5-dimethyl-4-prop-2-enoylpiperazin-1-yl]-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-methylsulfonyl-6-propan-2-ylphenyl)pyrido[2,3-d]pyrimidin-2-one",637.700,C32H33F2N5O5S,132.000,1280.000,4.300,45,1,8,6,"InChI=1S/C32H33F2N5O5S/c1-7-26(41)37-15-19(5)38(16-18(37)4)30-21-14-23(34)28(27-22(33)11-9-12-24(27)40)35-31(21)39(32(42)36-30)29-20(17(2)3)10-8-13-25(29)45(6,43)44/h7-14,17-19,40H,1,15-16H2,2-6H3/t18-,19+/m1/s1",C[C@@H]1CN([C@H](CN1C(=O)C=C)C)C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)O)C5=C(C=CC=C5S(=O)(=O)C)C(C)C,CC1CN(C(CN1C(=O)C=C)C)C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)O)C5=C(C=CC=C5S(=O)(=O)C)C(C)C,DVYNJKUHECHEDC-MOPGFXCFSA-N,"4-[(2S,5R)-2,5-dimethyl-4-prop-2-enoylpiperazin-1-yl]-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-methylsulfonyl-6-propan-2-ylphenyl)pyrido[2,3-d]pyrimidin-2-one",637.217,637.217,0,1,0,2,2,0,0,0,0,0,2,2,"",Classification|Patents,2,"",20211110,"AbaChemScene|Debye Scientific Co., Ltd|Google Patents|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
156768584,KRAS G12C inhibitor 35,KRAS G12C inhibitor 35|2650550-87-9|DA-74794|HY-143588|CS-0373866,605.000,C31H27ClF2N6O3,114.000,1170.000,4.600,43,1,9,5,"InChI=1S/C31H27ClF2N6O3/c1-5-23(42)38-10-12-39(13-11-38)29-18-14-21(33)27(24-22(41)7-6-20(32)25(24)34)37-30(18)40(31(43)19(29)15-35)28-17(4)8-9-36-26(28)16(2)3/h5-9,14,16,41H,1,10-13H2,2-4H3",CC1=C(C(=NC=C1)C(C)C)N2C3=NC(=C(C=C3C(=C(C2=O)C#N)N4CCN(CC4)C(=O)C=C)F)C5=C(C=CC(=C5F)Cl)O,CC1=C(C(=NC=C1)C(C)C)N2C3=NC(=C(C=C3C(=C(C2=O)C#N)N4CCN(CC4)C(=O)C=C)F)C5=C(C=CC(=C5F)Cl)O,VKOUGWHSWXDAGP-UHFFFAOYSA-N,"7-(3-chloro-2-fluoro-6-hydroxyphenyl)-6-fluoro-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxo-4-(4-prop-2-enoylpiperazin-1-yl)-1,8-naphthyridine-3-carbonitrile",604.18,604.18,0,1,0,0,0,0,0,0,0,0,0,0,"",Classification|Patents,2,"",20211110,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|MedChemexpress MCE|PATENTSCOPE (WIPO)|TargetMol",Chemical Vendors|Governmental Organizations,""
156766505,KRAS G12C inhibitor 33,"KRAS G12C inhibitor 33|2648985-02-6|SCHEMBL25248712|DA-74793|HY-142490|CS-0372530|2-methyl-6-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-3-naphthalen-1-yl-8-(4-prop-2-enoylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-4-one",539.600,C30H33N7O3,94.500,982.000,3.500,40,0,8,6,"InChI=1S/C30H33N7O3/c1-4-25(38)35-15-17-36(18-16-35)28-26-27(32-30(33-28)40-19-22-11-8-14-34(22)3)29(39)37(20(2)31-26)24-13-7-10-21-9-5-6-12-23(21)24/h4-7,9-10,12-13,22H,1,8,11,14-19H2,2-3H3/t22-/m0/s1",CC1=NC2=C(C(=O)N1C3=CC=CC4=CC=CC=C43)N=C(N=C2N5CCN(CC5)C(=O)C=C)OC[C@@H]6CCCN6C,CC1=NC2=C(C(=O)N1C3=CC=CC4=CC=CC=C43)N=C(N=C2N5CCN(CC5)C(=O)C=C)OCC6CCCN6C,BZZYACFDPKVXKG-QFIPXVFZSA-N,"2-methyl-6-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-3-naphthalen-1-yl-8-(4-prop-2-enoylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-4-one",539.264,539.264,0,1,0,1,1,0,0,0,0,0,0,0,"",Patents,1,"",20211110,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
156554934,KRAS G12C inhibitor 41,"KRAS G12C inhibitor 41|2660014-65-1|SCHEMBL23598802|DA-74796|HY-143596|CS-0373936|2-[(2S)-4-[7-(8-chloro-7-fluoronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-pyrimidin-5-ylprop-2-enoyl)piperazin-2-yl]acetonitrile",682.200,C36H37ClFN9O2,115.000,1220.000,4.800,49,0,11,8,"InChI=1S/C36H37ClFN9O2/c1-23(25-17-40-22-41-18-25)35(48)47-16-15-46(19-26(47)10-12-39)34-28-11-14-45(31-7-3-5-24-8-9-29(38)33(37)32(24)31)20-30(28)42-36(43-34)49-21-27-6-4-13-44(27)2/h3,5,7-9,17-18,22,26-27H,1,4,6,10-11,13-16,19-21H2,2H3/t26-,27-/m0/s1",CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=C(C=C5)F)Cl)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C(=C)C7=CN=CN=C7,CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=C(C=C5)F)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=C)C7=CN=CN=C7,INJGVJAHNUVYJU-SVBPBHIXSA-N,"2-[(2S)-4-[7-(8-chloro-7-fluoronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-pyrimidin-5-ylprop-2-enoyl)piperazin-2-yl]acetonitrile",681.274,681.274,0,1,0,2,2,0,0,0,0,0,1,1,"",Classification|Patents,2,"",20210821,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|Google Patents|InvivoChem|MedChemexpress MCE|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Research and Development,""
156554845,KRAS G12C inhibitor 40,"KRAS G12C inhibitor 40|2660014-14-0|SCHEMBL23598706|DA-64774|HY-143594|CS-0373933|2-[(2S)-4-[7-(8-chloro-7-fluoronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-[(E)-3-(1,2,4-triazol-1-yl)prop-2-enoyl]piperazin-2-yl]acetonitrile",671.200,C34H36ClFN10O2,120.000,1190.000,4.200,48,0,11,8,"InChI=1S/C34H36ClFN10O2/c1-42-13-3-5-25(42)20-48-34-40-28-19-43(29-6-2-4-23-7-8-27(36)32(35)31(23)29)14-10-26(28)33(41-34)44-16-17-46(24(18-44)9-12-37)30(47)11-15-45-22-38-21-39-45/h2,4,6-8,11,15,21-22,24-25H,3,5,9-10,13-14,16-20H2,1H3/b15-11+/t24-,25-/m0/s1",CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=C(C=C5)F)Cl)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)/C=C/N7C=NC=N7,CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=C(C=C5)F)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C=CN7C=NC=N7,BLVBQVLTXVPOLH-LPMFOMBZSA-N,"2-[(2S)-4-[7-(8-chloro-7-fluoronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-[(E)-3-(1,2,4-triazol-1-yl)prop-2-enoyl]piperazin-2-yl]acetonitrile",670.27,670.27,0,1,0,2,2,0,1,1,0,0,1,1,"",Classification|Patents,2,"",20210821,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|InvivoChem|MedChemexpress MCE|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Research and Development,""
156546145,KRAS G12C inhibitor 38,KRAS G12C inhibitor 38|2660324-77-4|SCHEMBL23588659|DA-74795|HY-143591|CS-0373916,700.800,C38H43F3N8O2,93.700,1270.000,6.900,51,1,11,8,"InChI=1S/C38H43F3N8O2/c1-3-30(50)49-20-37(21-49)10-14-47(15-11-37)35-27-16-26(24-7-8-24)32(31-23(2)6-9-29-28(31)17-42-45-29)34(51-22-38(39,40)41)33(27)43-36(44-35)48-18-25(19-48)46-12-4-5-13-46/h3,6,9,16-17,24-25H,1,4-5,7-8,10-15,18-22H2,2H3,(H,42,45)",CC1=C(C2=C(C=C1)NN=C2)C3=C(C=C4C(=C3OCC(F)(F)F)N=C(N=C4N5CCC6(CC5)CN(C6)C(=O)C=C)N7CC(C7)N8CCCC8)C9CC9,CC1=C(C2=C(C=C1)NN=C2)C3=C(C=C4C(=C3OCC(F)(F)F)N=C(N=C4N5CCC6(CC5)CN(C6)C(=O)C=C)N7CC(C7)N8CCCC8)C9CC9,PBENVJNCTVARNW-UHFFFAOYSA-N,"1-[7-[6-cyclopropyl-7-(5-methyl-1H-indazol-4-yl)-2-(3-pyrrolidin-1-ylazetidin-1-yl)-8-(2,2,2-trifluoroethoxy)quinazolin-4-yl]-2,7-diazaspiro[3.5]nonan-2-yl]prop-2-en-1-one",700.346,700.346,0,1,0,0,0,0,0,0,0,0,1,1,"",Classification|Patents,2,"",20210821,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
156472654,KRAS G12C inhibitor 18,"KRAS G12C inhibitor 18|2649788-45-2|SCHEMBL23496744|AKOS040757942|DA-64767|HY-132979|CS-0311439|4-[(13aS)-10-chloro-8-fluoro-6-oxo-2-prop-2-enoyl-1,3,4,12,13,13a-hexahydropyrazino[2,1-d][1,5]benzoxazocin-9-yl]-2-amino-1-benzothiophene-3-carbonitrile",511.000,C25H20ClFN4O3S,128.000,916.000,4.700,35,1,7,2,"InChI=1S/C25H20ClFN4O3S/c1-2-19(32)30-7-8-31-13(12-30)6-9-34-23-15(25(31)33)10-17(27)21(22(23)26)14-4-3-5-18-20(14)16(11-28)24(29)35-18/h2-5,10,13H,1,6-9,12,29H2/t13-/m0/s1",C=CC(=O)N1CCN2[C@H](C1)CCOC3=C(C(=C(C=C3C2=O)F)C4=C5C(=CC=C4)SC(=C5C#N)N)Cl,C=CC(=O)N1CCN2C(C1)CCOC3=C(C(=C(C=C3C2=O)F)C4=C5C(=CC=C4)SC(=C5C#N)N)Cl,FLOCSULDJZSEOQ-ZDUSSCGKSA-N,"4-[(13aS)-10-chloro-8-fluoro-6-oxo-2-prop-2-enoyl-1,3,4,12,13,13a-hexahydropyrazino[2,1-d][1,5]benzoxazocin-9-yl]-2-amino-1-benzothiophene-3-carbonitrile",510.093,510.093,0,1,0,1,1,0,0,0,0,0,3,1,"",Classification|Patents,2,"",20210821,"AbaChemScene|AKos Consulting & Solutions|BOC Sciences|Debye Scientific Co., Ltd|Google Patents|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
156472638,KRAS G12C inhibitor 19,"KRAS G12C inhibitor 19|2649788-46-3|Olomorasib|LY3537982|2-Amino-4-[(4aS)-8-chloro-10-fluoro-2,3,4,4a,5,6-hexahydro-12-oxo-3-(1-oxo-2-propen-1-yl)-1H,12H-pyrazino[2,1-d][1,5]benzoxazocin-9-yl]-7-fluorobenzo[b]thiophene-3-carbonitrile|OLOMORASIB [USAN]|C2VJ83PSN7|SCHEMBL23496727|(4R)-2-Amino-4-[(4aS)-8-chloro-10-fluoro-2,3,4,4a,5,6-hexahydro-12-oxo-3-(1-oxo-2-propen-1-yl)-1H,12H-pyrazino[2,1-d][1,5]benzoxazocin-9-yl]-7-fluorobenzo[b]thiophene-3-carbonitrile|EX-A6653|NSC853962|AKOS040757943|NSC-853962|DA-64768|HY-132980|CS-0311440|LY-3537982|F78016|2-amino-4-[(4aS)-8-chloro-10-fluoro-2,3,4,4a,5,6-hexahydro-12-oxo-3-(1-oxo-2-propen-1-yl)-1H,12H-pyrazino[2,1-d][1,5]benzoxazocin-9-yl]-7-fluoro-Benzo[b]thiophene-3-carbonitrile|2-Amino-4-[(4R)-8-chloro-10-fluoro-12-oxo-3-(prop-2-enoyl)-2,3,4,4a,5,6-hexahydro-1H,12H-pyrazino[2,1-d][1,5]benzoxazocin-9-yl]-7-fluoro-1-benzothiophene-3-carbonitrile|4-((S)-3-ACRYLOYL-8-CHLORO-10-FLUORO-12-OXO-2,3,4,4A,5,6-HEXAHYDRO-1H,12H-BENZO[B]PYRAZINO[1,2-E][1,5]OXAZOCIN-9-YL)-2-AMINO-7-FLUOROBENZO[B]THIOPHENE-3-CARBONITRILE|4-[(13aS)-10-chloro-8-fluoro-6-oxo-2-prop-2-enoyl-1,3,4,12,13,13a-hexahydropyrazino[2,1-d][1,5]benzoxazocin-9-yl]-2-amino-7-fluoro-1-benzothiophene-3-carbonitrile|Benzo[b]thiophene-3-carbonitrile, 2-amino-4-[(4aS)-8-chloro-10-fluoro-2,3,4,4a,5,6-hexahydro-12-oxo-3-(1-oxo-2-propen-1-yl)-1H,12H-pyrazino[2,1-d][1,5]benzoxazocin-9-yl]-7-fluoro-, (4R)-",529.000,C25H19ClF2N4O3S,128.000,952.000,4.800,36,1,8,2,"InChI=1S/C25H19ClF2N4O3S/c1-2-18(33)31-6-7-32-12(11-31)5-8-35-22-14(25(32)34)9-17(28)20(21(22)26)13-3-4-16(27)23-19(13)15(10-29)24(30)36-23/h2-4,9,12H,1,5-8,11,30H2/t12-/m0/s1",C=CC(=O)N1CCN2[C@H](C1)CCOC3=C(C(=C(C=C3C2=O)F)C4=C5C(=C(SC5=C(C=C4)F)N)C#N)Cl,C=CC(=O)N1CCN2C(C1)CCOC3=C(C(=C(C=C3C2=O)F)C4=C5C(=C(SC5=C(C=C4)F)N)C#N)Cl,OZUPICRWMLEFCS-LBPRGKRZSA-N,"4-[(13aS)-10-chloro-8-fluoro-6-oxo-2-prop-2-enoyl-1,3,4,12,13,13a-hexahydropyrazino[2,1-d][1,5]benzoxazocin-9-yl]-2-amino-7-fluoro-1-benzothiophene-3-carbonitrile",528.083,528.083,0,1,0,1,1,0,0,0,0,0,1,1,"",Classification|Drug and Medication Information|Patents,3,"",20210821,"10X CHEM|A2B Chem|AA BLOCKS|AbaChemScene|AKos Consulting & Solutions|Amadis Chemical|AstaTech, Inc.|BLD Pharm|BOC Sciences|Chem-Space.com Database|Debye Scientific Co., Ltd|DTP/NCI|Excenen Pharmatech|FDA Global Substance Registration System (GSRS)|Google Patents|InvivoChem|Mcule|MedChemexpress MCE|MolPort|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
156461328,KRAS G12C inhibitor 26,"KRAS G12C inhibitor 26|2648584-52-3|SCHEMBL23481500|DA-54667|HY-142457|CS-0372422|2-[(2S)-1-(2-fluoroprop-2-enoyl)-4-[(7S)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile",588.600,C29H32F4N6O3,94.800,1020.000,3.600,42,0,12,7,"InChI=1S/C29H32F4N6O3/c1-18(30)27(40)39-13-12-38(15-19(39)9-10-34)26-22-17-41-25(21-7-3-4-8-23(21)29(31,32)33)14-24(22)35-28(36-26)42-16-20-6-5-11-37(20)2/h3-4,7-8,19-20,25H,1,5-6,9,11-17H2,2H3/t19-,20-,25-/m0/s1",CN1CCC[C@H]1COC2=NC3=C(CO[C@@H](C3)C4=CC=CC=C4C(F)(F)F)C(=N2)N5CCN([C@H](C5)CC#N)C(=O)C(=C)F,CN1CCCC1COC2=NC3=C(COC(C3)C4=CC=CC=C4C(F)(F)F)C(=N2)N5CCN(C(C5)CC#N)C(=O)C(=C)F,QHAKQJHNFQRVOF-RLSLOFABSA-N,"2-[(2S)-1-(2-fluoroprop-2-enoyl)-4-[(7S)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile",588.247,588.247,0,1,0,3,3,0,0,0,0,0,2,1,"",Classification|Patents,2,"",20210821,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
156461319,KRAS G12C inhibitor 27,"KRAS G12C inhibitor 27|2648584-51-2|SCHEMBL23481490|DA-54668|HY-142458|CS-0372427|2-[(2S)-1-(2-fluoroprop-2-enoyl)-4-[(7R)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile",588.600,C29H32F4N6O3,94.800,1020.000,3.600,42,0,12,7,"InChI=1S/C29H32F4N6O3/c1-18(30)27(40)39-13-12-38(15-19(39)9-10-34)26-22-17-41-25(21-7-3-4-8-23(21)29(31,32)33)14-24(22)35-28(36-26)42-16-20-6-5-11-37(20)2/h3-4,7-8,19-20,25H,1,5-6,9,11-17H2,2H3/t19-,20-,25+/m0/s1",CN1CCC[C@H]1COC2=NC3=C(CO[C@H](C3)C4=CC=CC=C4C(F)(F)F)C(=N2)N5CCN([C@H](C5)CC#N)C(=O)C(=C)F,CN1CCCC1COC2=NC3=C(COC(C3)C4=CC=CC=C4C(F)(F)F)C(=N2)N5CCN(C(C5)CC#N)C(=O)C(=C)F,QHAKQJHNFQRVOF-ZYLNGJIFSA-N,"2-[(2S)-1-(2-fluoroprop-2-enoyl)-4-[(7R)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile",588.247,588.247,0,1,0,3,3,0,0,0,0,0,2,1,"",Classification|Patents,2,"",20210821,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
156443495,KRAS G12C inhibitor 28,"KRAS G12C inhibitor 28|2649004-88-4|SCHEMBL23460319|DA-74790|HY-142460|CS-0372433|1-(4-dimethylphosphoryl-2-methyl-6-propan-2-ylphenyl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one",635.600,C33H36F2N5O4P,106.000,1210.000,4.000,45,1,7,6,"InChI=1S/C33H36F2N5O4P/c1-8-27(42)38-12-13-39(20(5)17-38)31-23-16-25(35)29(28-24(34)10-9-11-26(28)41)36-32(23)40(33(43)37-31)30-19(4)14-21(45(6,7)44)15-22(30)18(2)3/h8-11,14-16,18,20,41H,1,12-13,17H2,2-7H3/t20-/m0/s1",C[C@H]1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)O)C5=C(C=C(C=C5C)P(=O)(C)C)C(C)C)C(=O)C=C,CC1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)O)C5=C(C=C(C=C5C)P(=O)(C)C)C(C)C)C(=O)C=C,AULVAQHFJPQQED-FQEVSTJZSA-N,"1-(4-dimethylphosphoryl-2-methyl-6-propan-2-ylphenyl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one",635.247,635.247,0,1,0,1,1,0,0,0,0,0,1,1,"",Classification|Patents,2,"",20210821,"10X CHEM|A2B Chem|AbaChemScene|Amadis Chemical|BLD Pharm|Debye Scientific Co., Ltd|eNovation Chemicals|InvivoChem|Mcule|MedChemexpress MCE|MolPort|PATENTSCOPE (WIPO)|Probes & Drugs portal|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
156303062,KRAS G12C inhibitor 20,"KRAS G12C inhibitor 20|2640858-10-0|SCHEMBL23282328|DA-54664|HY-145017|CS-0312203|2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[3-(methoxymethyl)-1-methylazetidin-3-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile",634.100,C33H37ClFN7O3,98.100,1120.000,4.200,45,0,10,9,"InChI=1S/C33H37ClFN7O3/c1-22(35)31(43)42-15-14-41(16-24(42)10-12-36)30-25-11-13-40(28-9-5-7-23-6-4-8-26(34)29(23)28)17-27(25)37-32(38-30)45-21-33(20-44-3)18-39(2)19-33/h4-9,24H,1,10-11,13-21H2,2-3H3/t24-/m0/s1",CN1CC(C1)(COC)COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C(=C)F,CN1CC(C1)(COC)COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=C)F,WGNKFEDTYNVQAY-DEOSSOPVSA-N,"2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[3-(methoxymethyl)-1-methylazetidin-3-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile",633.263,633.263,0,1,0,1,1,0,0,0,0,0,2,1,"",Classification|Patents,2,"",20210821,"AbaChemScene|BLD Pharm|BOC Sciences|Debye Scientific Co., Ltd|InvivoChem|MedChemexpress MCE|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Research and Development,""
156295495,KRAS G12C inhibitor 46,"KRAS G12C inhibitor 46|2573769-23-8|SCHEMBL23272791|DA-64775|HY-142948|CS-0374015|16,19-difluoro-22-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]-3-propan-2-yl-1,4,11,23,26-pentazapentacyclo[16.6.2.02,7.012,17.021,25]hexacosa-2(7),3,5,12(17),13,15,18,20,22,25-decaen-24-one",585.600,C32H33F2N7O2,94.000,1090.000,4.300,43,1,7,3,"InChI=1S/C32H33F2N7O2/c1-5-25(42)39-14-15-40(19(4)17-39)30-21-16-23(34)28-26-22(33)9-6-10-24(26)35-12-7-8-20-11-13-36-27(18(2)3)29(20)41(31(21)37-28)32(43)38-30/h5-6,9-11,13,16,18-19,35H,1,7-8,12,14-15,17H2,2-4H3/t19-/m0/s1",C[C@H]1CN(CCN1C2=NC(=O)N3C4=C(CCCNC5=C(C(=CC=C5)F)C6=C(C=C2C3=N6)F)C=CN=C4C(C)C)C(=O)C=C,CC1CN(CCN1C2=NC(=O)N3C4=C(CCCNC5=C(C(=CC=C5)F)C6=C(C=C2C3=N6)F)C=CN=C4C(C)C)C(=O)C=C,FFCREROHVMKRFT-IBGZPJMESA-N,"16,19-difluoro-22-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]-3-propan-2-yl-1,4,11,23,26-pentazapentacyclo[16.6.2.02,7.012,17.021,25]hexacosa-2(7),3,5,12(17),13,15,18,20,22,25-decaen-24-one",585.266,585.266,0,1,0,1,1,0,0,0,0,0,3,2,"",Classification|Patents,2,"",20210821,"AbaChemScene|Debye Scientific Co., Ltd|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
154644326,KRAS G12C inhibitor 42,"KRAS G12C inhibitor 42|2454488-02-7|SCHEMBL22220331|DA-74797|HY-143598|CS-0373939|2-[(2S)-4-[8-fluoro-7-(8-methylnaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",579.700,C33H34FN7O2,98.500,1040.000,4.800,43,0,9,7,"InChI=1S/C33H34FN7O2/c1-4-27(42)41-17-16-40(19-23(41)13-14-35)32-26-18-36-30(25-12-6-10-22-9-5-8-21(2)28(22)25)29(34)31(26)37-33(38-32)43-20-24-11-7-15-39(24)3/h4-6,8-10,12,18,23-24H,1,7,11,13,15-17,19-20H2,2-3H3/t23-,24-/m0/s1",CC1=C2C(=CC=C1)C=CC=C2C3=NC=C4C(=C3F)N=C(N=C4N5CCN([C@H](C5)CC#N)C(=O)C=C)OC[C@@H]6CCCN6C,CC1=C2C(=CC=C1)C=CC=C2C3=NC=C4C(=C3F)N=C(N=C4N5CCN(C(C5)CC#N)C(=O)C=C)OCC6CCCN6C,JCIQWPCUVDTKAS-ZEQRLZLVSA-N,"2-[(2S)-4-[8-fluoro-7-(8-methylnaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",579.276,579.276,0,1,0,2,2,0,0,0,0,0,3,1,"",Classification|Patents,2,"",20200928,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|Google Patents|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
146624881,Divarasib,"Divarasib|GDC-6036|2417987-45-0|GDC6036|Divarasib [INN]|RG6330|RG-6330|Gdc 6036|E6S21PVT91|1-[(3S)-4-[7-[6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl]-6-chloro-8-fluoro-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]quinazolin-4-yl]-3-methylpiperazin-1-yl]prop-2-en-1-one|RO7435846|1-((3S)-4-((7m)-7-(6-Amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2S)-1-methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one|2-Propen-1-one, 1-((3S)-4-((7R)-7-(6-amino-4-methyl-3-(trifluoromethyl)-2-pyridinyl)-6-chloro-8-fluoro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)-4-quinazolinyl)-3-methyl-1-piperazinyl)-|2417917-17-8|1-((3S)-4-(7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2S)-1-methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one|1-{(3S)-4-[(7M)-7-[6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl]-6-chloro-8-fluoro-2-{[(2S)-1-methylpyrrolidin-2-yl]methoxy}quinazolin-4-yl]-3-methylpiperazin-1-yl}prop-2-en-1-one|2-Propen-1-one, 1-[(3S)-4-[(7R)-7-[6-amino-4-methyl-3-(trifluoromethyl)-2-pyridinyl]-6-chloro-8-fluoro-2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]-4-quinazolinyl]-3-methyl-1-piperazinyl]-|Divarasib [WHO-DD]|DIVARASIB [USAN]|UNII-E6S21PVT91|CHEMBL5095236|SCHEMBL22028856|GTPL11963|GDC 6036 [WHO-DD]|ZRBPIAWWRPFDPY-IRXDYDNUSA-N|BDBM535152|GLXC-25585|GLXC-27763|EX-A5694|US11236068, Example 17a|US11236068, Example 17b|KRAS G12C Inhibitor GDC-6036|NSC841802|AT41886|NSC-841802|MS-30794|HY-145928|CS-0435408|RO-7435846|1-((3S)-4-(7-(6-Amino-4-methyl-3-(trifluoromethyl)-2-pyridyl)-6-chloro-8-fluoro-2-(((2S)-1-methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one|1-((3S)-4-(7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one|1-((S)-4-((R)-7-(6-Amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one|1-[(3S)-4-[(7R)-7-[6-Amino-4-methyl-3-(trifluoromethyl)-2-pyridinyl]-6-chloro-8-fluoro-2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]-4-quinazolinyl]-3-methyl-1-piperazinyl]-2-propen-1-one",622.100,C29H32ClF4N7O2,101.000,997.000,5.400,43,1,12,6,"InChI=1S/C29H32ClF4N7O2/c1-5-21(42)40-9-10-41(16(3)13-40)27-18-12-19(30)22(26-23(29(32,33)34)15(2)11-20(35)36-26)24(31)25(18)37-28(38-27)43-14-17-7-6-8-39(17)4/h5,11-12,16-17H,1,6-10,13-14H2,2-4H3,(H2,35,36)/t16-,17-/m0/s1",C[C@H]1CN(CCN1C2=NC(=NC3=C(C(=C(C=C32)Cl)C4=C(C(=CC(=N4)N)C)C(F)(F)F)F)OC[C@@H]5CCCN5C)C(=O)C=C,CC1CN(CCN1C2=NC(=NC3=C(C(=C(C=C32)Cl)C4=C(C(=CC(=N4)N)C)C(F)(F)F)F)OCC5CCCN5C)C(=O)C=C,ZRBPIAWWRPFDPY-IRXDYDNUSA-N,1-[(3S)-4-[7-[6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl]-6-chloro-8-fluoro-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]quinazolin-4-yl]-3-methylpiperazin-1-yl]prop-2-en-1-one,621.224,621.224,0,1,0,2,2,0,0,0,0,3,12,6,"",Biological Test Results|Interactions and Pathways|Classification|Drug and Medication Information|Literature|Patents|Associated Disorders and Diseases|Biological Test Results: Active|Biological Test Results: Micromolar,9,1|3|5|7|9|13|15|19|21|23|25|29|33|35|37|39|41|43|45|47|49|53|55|59|65|67|71|73|77|79|81|83|85|89|91|93|95|97|99|101|103|105|107|109|113|115|119|121|123|125|129|131|133|137|139|141|143|145|1806303|1871172|1871173|1871174,20200627,"10X CHEM|A2B Chem|AbaChemScene|AbMole Bioscience|Allbio Pharm Co., Ltd|Amadis Chemical|Angel Pharmatech Ltd.|AstaTech, Inc.|Axon Medchem|BindingDB|BOC Sciences|ChEMBL|ChemIDplus|ChemShuttle|DTP/NCI|ECI Group, LCSB, University of Luxembourg|Excenen Pharmatech|FDA Global Substance Registration System (GSRS)|Glixx Labs Inc|Google Patents|InvivoChem|IUPHAR/BPS Guide to PHARMACOLOGY|Key Organics/BIONET|Mcule|MedChemexpress MCE|MolGenie|PATENTSCOPE (WIPO)|Probes & Drugs portal|PubChem Reference Collection|Starshine Chemical|SureChEMBL",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1902 - Ras Inhibitor|C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor
139520657,KRAS G12C inhibitor 37,"KRAS G12C inhibitor 37|2241720-04-5|SCHEMBL21393650|AHOBXXAGZPGARY-UHFFFAOYSA-N|1-[7-[2-[3-(dimethylamino)azetidin-1-yl]-6-ethenyl-7-(5-methyl-1H-indazol-4-yl)-8-(2,2,2-trifluoroethoxy)quinazolin-4-yl]-2,7-diazaspiro[3.5]nonan-2-yl]prop-2-en-1-one|DA-64772|HY-143590|CS-0373903",660.700,C35H39F3N8O2,93.700,1180.000,6.300,48,1,11,8,"InChI=1S/C35H39F3N8O2/c1-6-22-14-24-30(31(48-20-35(36,37)38)29(22)28-21(3)8-9-26-25(28)15-39-42-26)40-33(45-16-23(17-45)43(4)5)41-32(24)44-12-10-34(11-13-44)18-46(19-34)27(47)7-2/h6-9,14-15,23H,1-2,10-13,16-20H2,3-5H3,(H,39,42)",CC1=C(C2=C(C=C1)NN=C2)C3=C(C4=C(C=C3C=C)C(=NC(=N4)N5CC(C5)N(C)C)N6CCC7(CC6)CN(C7)C(=O)C=C)OCC(F)(F)F,CC1=C(C2=C(C=C1)NN=C2)C3=C(C4=C(C=C3C=C)C(=NC(=N4)N5CC(C5)N(C)C)N6CCC7(CC6)CN(C7)C(=O)C=C)OCC(F)(F)F,AHOBXXAGZPGARY-UHFFFAOYSA-N,"1-[7-[2-[3-(dimethylamino)azetidin-1-yl]-6-ethenyl-7-(5-methyl-1H-indazol-4-yl)-8-(2,2,2-trifluoroethoxy)quinazolin-4-yl]-2,7-diazaspiro[3.5]nonan-2-yl]prop-2-en-1-one",660.315,660.315,0,1,0,0,0,0,0,0,0,0,6,2,"",Classification|Patents,2,"",20191102,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|ECI Group, LCSB, University of Luxembourg|Google Patents|InvivoChem|MedChemexpress MCE|MolGenie|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
138911339,KRAS G12C inhibitor 13,KRAS G12C inhibitor 13|2241719-75-3|SCHEMBL21379069|MODIEPRURJWGTG-UHFFFAOYSA-N|AKOS040733537|DA-74787|HY-126292|CS-0101474,745.800,C40H46F3N7O4,109.000,1310.000,7.200,54,1,12,9,"InChI=1S/C40H46F3N7O4/c1-4-26-20-29-35(36(53-24-40(41,42)43)34(26)33-25(3)6-7-31-30(33)21-44-47-31)45-38(54-28-8-14-48(15-9-28)27-10-18-52-19-11-27)46-37(29)49-16-12-39(13-17-49)22-50(23-39)32(51)5-2/h4-7,20-21,27-28H,1-2,8-19,22-24H2,3H3,(H,44,47)",CC1=C(C2=C(C=C1)NN=C2)C3=C(C4=C(C=C3C=C)C(=NC(=N4)OC5CCN(CC5)C6CCOCC6)N7CCC8(CC7)CN(C8)C(=O)C=C)OCC(F)(F)F,CC1=C(C2=C(C=C1)NN=C2)C3=C(C4=C(C=C3C=C)C(=NC(=N4)OC5CCN(CC5)C6CCOCC6)N7CCC8(CC7)CN(C8)C(=O)C=C)OCC(F)(F)F,MODIEPRURJWGTG-UHFFFAOYSA-N,"1-[7-[6-ethenyl-7-(5-methyl-1H-indazol-4-yl)-2-[1-(oxan-4-yl)piperidin-4-yl]oxy-8-(2,2,2-trifluoroethoxy)quinazolin-4-yl]-2,7-diazaspiro[3.5]nonan-2-yl]prop-2-en-1-one",745.356,745.356,0,1,0,0,0,0,0,0,0,0,9,2,"",Classification|Patents,2,"",20190902,"A2B Chem|AA BLOCKS|AbaChemScene|AKos Consulting & Solutions|BOC Sciences|CymitQuimica|Debye Scientific Co., Ltd|ECI Group, LCSB, University of Luxembourg|Google Patents|Lan Pharmatech|Mcule|MedChemexpress MCE|MolGenie|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Legacy Depositors|Research and Development,""
138721313,KRAS G12C inhibitor 17,"KRAS G12C inhibitor 17|2349393-04-8|SCHEMBL21099618|AKOS040733541|DA-54663|HY-125875|CS-0102610|1-[(4R,7R)-16-chloro-14-fluoro-15-(2-fluoro-6-hydroxyphenyl)-4-methyl-9-oxa-2,5,12-triazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),11,13,15,17-pentaen-5-yl]prop-2-en-1-one",471.900,C24H20ClF2N3O3,65.900,763.000,4.500,33,1,7,2,"InChI=1S/C24H20ClF2N3O3/c1-3-19(32)29-10-13-11-33-18-8-28-23-14(24(18)30(13)9-12(29)2)7-15(25)20(22(23)27)21-16(26)5-4-6-17(21)31/h3-8,12-13,31H,1,9-11H2,2H3/t12-,13-/m1/s1",C[C@@H]1CN2[C@H](CN1C(=O)C=C)COC3=C2C4=CC(=C(C(=C4N=C3)F)C5=C(C=CC=C5F)O)Cl,CC1CN2C(CN1C(=O)C=C)COC3=C2C4=CC(=C(C(=C4N=C3)F)C5=C(C=CC=C5F)O)Cl,VUKUQOCNPKSWQJ-CHWSQXEVSA-N,"1-[(4R,7R)-16-chloro-14-fluoro-15-(2-fluoro-6-hydroxyphenyl)-4-methyl-9-oxa-2,5,12-triazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),11,13,15,17-pentaen-5-yl]prop-2-en-1-one",471.116,471.116,0,1,0,2,2,0,0,0,0,0,2,1,"",Classification|Patents,2,"",20190720,"AbaChemScene|AKos Consulting & Solutions|BOC Sciences|CymitQuimica|Debye Scientific Co., Ltd|Google Patents|InvivoChem|Mcule|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
138678786,KRAS G12C inhibitor 16,"KRAS G12C inhibitor 16|2349392-79-4|CHEMBL4567284|SCHEMBL21050662|BDBM50527046|AKOS040733540|DA-64766|PD168385|HY-125874|CS-0102608|1-[(7R)-16-chloro-15-(2-fluoro-6-hydroxyphenyl)-14-methyl-9-oxa-2,5,12-triazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),11,13,15,17-pentaen-5-yl]prop-2-en-1-one",453.900,C24H21ClFN3O3,65.900,729.000,4.300,32,1,6,2,"InChI=1S/C24H21ClFN3O3/c1-3-20(31)28-7-8-29-14(11-28)12-32-19-10-27-23-13(2)21(16(25)9-15(23)24(19)29)22-17(26)5-4-6-18(22)30/h3-6,9-10,14,30H,1,7-8,11-12H2,2H3/t14-/m1/s1",CC1=C2C(=CC(=C1C3=C(C=CC=C3F)O)Cl)C4=C(C=N2)OC[C@@H]5N4CCN(C5)C(=O)C=C,CC1=C2C(=CC(=C1C3=C(C=CC=C3F)O)Cl)C4=C(C=N2)OCC5N4CCN(C5)C(=O)C=C,BATBWOGNVDIMCI-CQSZACIVSA-N,"1-[(7R)-16-chloro-15-(2-fluoro-6-hydroxyphenyl)-14-methyl-9-oxa-2,5,12-triazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),11,13,15,17-pentaen-5-yl]prop-2-en-1-one",453.126,453.126,0,1,0,1,1,0,0,0,0,0,2,1,"",Biological Test Results|Classification|Patents|Biological Test Results: Active|Biological Test Results: Micromolar,5,1605003|1605004|1605005|1605006,20190720,"AbaChemScene|AKos Consulting & Solutions|BindingDB|BOC Sciences|ChEMBL|CymitQuimica|Debye Scientific Co., Ltd|Google Patents|InvivoChem|Mcule|MedChemexpress MCE|MolGenie|MolPort|PATENTSCOPE (WIPO)|Probes & Drugs portal|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
138678756,KRAS G12C inhibitor 14,"KRAS G12C inhibitor 14|2349393-95-7|CHEMBL4452974|SCHEMBL21050632|BDBM50527059|AKOS040733538|MS-29015|HY-125872|CS-0102606|G16994|(7R)-16-chloro-14-fluoro-15-(2-fluoro-6-hydroxyphenyl)-9-methyl-5-prop-2-enoyl-2,5,9,12-tetrazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),11,13,15,17-pentaen-8-one",484.900,C24H19ClF2N4O3,77.000,836.000,3.500,34,1,7,2,"InChI=1S/C24H19ClF2N4O3/c1-3-18(33)30-7-8-31-16(11-30)24(34)29(2)15-10-28-22-12(23(15)31)9-13(25)19(21(22)27)20-14(26)5-4-6-17(20)32/h3-6,9-10,16,32H,1,7-8,11H2,2H3/t16-/m1/s1",CN1C2=C(C3=CC(=C(C(=C3N=C2)F)C4=C(C=CC=C4F)O)Cl)N5CCN(C[C@@H]5C1=O)C(=O)C=C,CN1C2=C(C3=CC(=C(C(=C3N=C2)F)C4=C(C=CC=C4F)O)Cl)N5CCN(CC5C1=O)C(=O)C=C,NZIBTXKFKUORFB-MRXNPFEDSA-N,"(7R)-16-chloro-14-fluoro-15-(2-fluoro-6-hydroxyphenyl)-9-methyl-5-prop-2-enoyl-2,5,9,12-tetrazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),11,13,15,17-pentaen-8-one",484.111,484.111,0,1,0,1,1,0,0,0,0,0,2,1,"",Biological Test Results|Classification|Patents|Biological Test Results: Active|Biological Test Results: Micromolar,5,1605000|1605003|1605004|1605005|1605006|1605007|1605008|1605009|1605010|1605011,20190720,"10X CHEM|A2B Chem|AbaChemScene|AKos Consulting & Solutions|Amadis Chemical|AstaTech, Inc.|BindingDB|BOC Sciences|ChEMBL|Google Patents|InvivoChem|Key Organics/BIONET|Mcule|MedChemexpress MCE|MolGenie|PATENTSCOPE (WIPO)|Probes & Drugs portal|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
138678754,KRAS G12C inhibitor 15,"KRAS G12C inhibitor 15|2349393-21-9|CHEMBL4461434|SCHEMBL21050629|GTPL10677|BDBM50527057|AKOS040733539|compound 25 [PMID: 32023060]|(2R,4aR)-11-Chloro-9-fluoro-10-(2-fluoro-6-hydroxyphenyl)-2,6-dimethyl-3-(prop-2-enoyl)-2,3,4,4a-tetrahydro-1H-pyrazino[1',2':4,5]pyrazino[2,3-c]quinolin-5(6H)-one|DA-74788|MS-29265|HY-125873|CS-0102607|G16995|(4R,7R)-16-chloro-14-fluoro-15-(2-fluoro-6-hydroxyphenyl)-4,9-dimethyl-5-prop-2-enoyl-2,5,9,12-tetrazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),11,13,15,17-pentaen-8-one",498.900,C25H21ClF2N4O3,77.000,867.000,3.900,35,1,7,2,"InChI=1S/C25H21ClF2N4O3/c1-4-19(34)31-11-17-25(35)30(3)16-9-29-23-13(24(16)32(17)10-12(31)2)8-14(26)20(22(23)28)21-15(27)6-5-7-18(21)33/h4-9,12,17,33H,1,10-11H2,2-3H3/t12-,17-/m1/s1",C[C@@H]1CN2[C@H](CN1C(=O)C=C)C(=O)N(C3=C2C4=CC(=C(C(=C4N=C3)F)C5=C(C=CC=C5F)O)Cl)C,CC1CN2C(CN1C(=O)C=C)C(=O)N(C3=C2C4=CC(=C(C(=C4N=C3)F)C5=C(C=CC=C5F)O)Cl)C,XDVMVEOFPVCHEL-SJKOYZFVSA-N,"(4R,7R)-16-chloro-14-fluoro-15-(2-fluoro-6-hydroxyphenyl)-4,9-dimethyl-5-prop-2-enoyl-2,5,9,12-tetrazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),11,13,15,17-pentaen-8-one",498.127,498.127,0,1,0,2,2,0,0,0,0,4,2,1,"",Biological Test Results|Interactions and Pathways|Classification|Literature|Patents|Biological Test Results: Active|Biological Test Results: Micromolar,7,1605000|1605001|1605002|1605003|1605004|1605005|1605006|1605007|1605008|1605009|1605010|1605011|1605012|1605013|1605014|1605015|1605016|1605017|1605018|1605019|1605020|1605021|1605022|1605023|1605024|1605025|1605026|1605027|1605028|1605029|1605030|1605031,20190720,"10X CHEM|A2B Chem|AbaChemScene|AKos Consulting & Solutions|Amadis Chemical|AstaTech, Inc.|BindingDB|BOC Sciences|ChEMBL|Combi-Blocks|CymitQuimica|Debye Scientific Co., Ltd|eNovation Chemicals|Google Patents|InvivoChem|IUPHAR/BPS Guide to PHARMACOLOGY|Key Organics/BIONET|Mcule|MedChemexpress MCE|MolGenie|MolPort|PATENTSCOPE (WIPO)|Probes & Drugs portal|SureChEMBL|TargetMol|Thieme Chemistry",Chemical Vendors|Curation Efforts|Governmental Organizations|Journal Publishers|Research and Development|Subscription Services,""
138611445,KRAS G12C inhibitor 39,"KRAS G12C inhibitor 39|2326522-16-9|SCHEMBL20975014|DA-64773|HY-143592|CS-0373926|2-[(2S)-4-[7-(8-methylnaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-[(E)-3-(1-methylpyrazol-4-yl)prop-2-enoyl]piperazin-2-yl]acetonitrile",645.800,C37H43N9O2,107.000,1180.000,4.300,48,0,9,8,"InChI=1S/C37H43N9O2/c1-26-7-4-8-28-9-5-11-33(35(26)28)44-18-15-31-32(24-44)40-37(48-25-30-10-6-17-42(30)2)41-36(31)45-19-20-46(29(23-45)14-16-38)34(47)13-12-27-21-39-43(3)22-27/h4-5,7-9,11-13,21-22,29-30H,6,10,14-15,17-20,23-25H2,1-3H3/b13-12+/t29-,30-/m0/s1",CC1=C2C(=CC=C1)C=CC=C2N3CCC4=C(C3)N=C(N=C4N5CCN([C@H](C5)CC#N)C(=O)/C=C/C6=CN(N=C6)C)OC[C@@H]7CCCN7C,CC1=C2C(=CC=C1)C=CC=C2N3CCC4=C(C3)N=C(N=C4N5CCN(C(C5)CC#N)C(=O)C=CC6=CN(N=C6)C)OCC7CCCN7C,XLWQRAXKTKNFIV-QFFHNCJUSA-N,"2-[(2S)-4-[7-(8-methylnaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-[(E)-3-(1-methylpyrazol-4-yl)prop-2-enoyl]piperazin-2-yl]acetonitrile",645.354,645.354,0,1,0,2,2,0,1,1,0,0,14,6,"",Patents,1,"",20190720,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|Google Patents|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
138611145,Adagrasib,"MRTX849|Adagrasib|2326521-71-3|MRTX-849|KRAZATI|Kras G12C inhibitor MRTX849|8EOO6HQF8Y|Adagrasib [USAN]|UNII-8EOO6HQF8Y|2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile|2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile|2-Piperazineacetonitrile, 4-[7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-|2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-|MFCD32263433|compound 20 (PMID: 32250617)|compound 20 [PMID: 32250617]|2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-{[(2S)-1-methylpyrrolidin-2-yl]methoxy}-5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile|2-((S)-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile|2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-{[(2S)-1-methylpyrrolidin-2-yl]methoxy}-5H,6H,8H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile|Krazati (TN)|ADAGRASIB [INN]|Adagrasib (USAN/INN)|MRTX849(Adagrasib)?|ADAGRASIB [WHO-DD]|MRTX 849|CHEMBL4594350|SCHEMBL20974691|GTPL10888|DTXSID801336759|BCP31538|EX-A3258|MRTX-849; MRTX 849|BDBM50539763|NSC831453|WHO 11519|AKOS037648997|AT23561|NSC-831453|AC-35659|BM177692|BS-16211|HY-130149|CS-0105265|D12301|EN300-26953032|Z4145344023|((2S)-4-(7-(8-CHLORONAPHTHALEN-1-YL)-2-(((2S)-1- METHYLPYRROLIDIN-2-YL)METHOXY)-5,6,7,8- TETRAHYDROPYRIDO(3,4-D)PYRIMIDIN-4-YL)-1-(2-FLUOROPROP2-ENOYL)PIPERAZIN-2-YL)ACETONITRILE|((2S)-4-(7-(8-CHLORONAPHTHALEN-1-YL)-2-(((2S)-1-METHYLPYRROLIDIN-2-YL)METHOXY)-5,6,7,8-TETRAHYDROPYRIDO(3,4-D)PYRIMIDIN-4-YL)-1-(2-FLUOROPROP2-ENOYL)PIPERAZIN-2-YL)ACETONITRILE",604.100,C32H35ClFN7O2,88.800,1060.000,5.000,43,0,9,7,"InChI=1S/C32H35ClFN7O2/c1-21(34)31(42)41-17-16-40(18-23(41)11-13-35)30-25-12-15-39(28-10-4-7-22-6-3-9-26(33)29(22)28)19-27(25)36-32(37-30)43-20-24-8-5-14-38(24)2/h3-4,6-7,9-10,23-24H,1,5,8,11-12,14-20H2,2H3/t23-,24-/m0/s1",CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C(=C)F,CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=C)F,PEMUGDMSUDYLHU-ZEQRLZLVSA-N,"2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile",603.252,603.252,0,1,0,2,2,0,0,0,0,79,42,25,"",Biological Test Results|Interactions and Pathways|Chemical and Physical Properties|Classification|Drug and Medication Information|Literature|Patents|Pharmacology and Biochemistry|Safety and Hazards|Toxicity|Use and Manufacturing|Associated Disorders and Diseases|Biological Test Results: Active|Biological Test Results: Micromolar,14,1|5|7|9|13|15|19|21|23|25|29|31|33|35|37|39|41|43|45|47|49|53|55|59|65|67|71|73|77|79|81|83|85|89|91|93|95|97|99|101|103|105|107|109|113|115|119|121|123|125|129|131|133|137|139|141|143|145|1652101|1652102|1652103|1652104|1652105|1652106|1652107|1652108|1652110|1652111|1652112|1652113|1652114|1652121|1652122|1652123|1652124|1652126|1652127|1652128|1652129|1652134|1652135|1652136|1652137|1652138|1652139|1652145|1652146|1652147|1652148|1652149|1652150|1652151|1652152|1652153|1652154|1652155|1652156|1652157|1652158|1652159|1652160|1652161|1652162|1652163|1652164|1652165|1652166|1652167|1652168|1652169|1652170|1652171|1652172|1652173|1652174|1652175|1652176|1670043|1671498|1694842|1694843|1694844|1697074|1697075|1818923|1818924|1818925|1818926|1835836|1836765|1838623|1839552|1840481|1841410|1842339|1843268|1844197|1853202|1889606|1889607|1889608|1893386|1893414|1893415|1893948|1915627|1915628|1915629|1915630|1915631|1937522,20190720,"001Chemical|10X CHEM|A2B Chem|AA BLOCKS|Aaron Chemicals LLC|AbaChemScene|abcr GmbH|AbMole Bioscience|AKos Consulting & Solutions|Allbio Pharm Co., Ltd|Amadis Chemical|Ambeed|Angel Pharmatech Ltd.|AppChem|AstaTech, Inc.|AvaChem Scientific|Axon Medchem|BenchChem|BindingDB|BioChemPartner|Biosynth|BLD Pharm|BOC Sciences|Chem-Space.com Database|ChEMBL|ChemIDplus|ChemShuttle|Combi-Blocks|CymitQuimica|DC Chemicals|DTP/NCI|Enamine|eNovation Chemicals|EPA DSSTox|Excenen Pharmatech|FDA Global Substance Registration System (GSRS)|Google Patents|Hangzhou APIChem Technology|Hunan Huateng Pharmaceutical Co., Ltd.|InvivoChem|IUPHAR/BPS Guide to PHARMACOLOGY|KEGG|Key Organics/BIONET|Lan Pharmatech|Mcule|MedChemexpress MCE|Molecule Market|MolGenie|MolPort|MuseChem|Nature Chemical Biology|PATENTSCOPE (WIPO)|Probes & Drugs portal|PubChem Reference Collection|Smolecule|Starshine Chemical|SureChEMBL|TargetMol|THE BioTek|Thieme Chemistry|Win-Win Chemical",Chemical Vendors|Curation Efforts|Governmental Organizations|Journal Publishers|Legacy Depositors|Research and Development|Subscription Services,C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1902 - Ras Inhibitor|C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor|D000970 - Antineoplastic Agents|L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents
138460837,KRAS G12C inhibitor 61,"KRAS G12C inhibitor 61|2300967-40-0|SCHEMBL20805274|BDBM550333|DA-54676|HY-156549|CS-0884179|US11306087, Ex. # 3|4-((2S,5R)-4-Acryloyl-2,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-6-chloro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one|4-((2S,5R,M)-4-Acryloyl-2,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-6-chloro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one",590.100,C31H33ClFN7O2,108.000,1060.000,4.600,42,1,6,5,"InChI=1S/C31H33ClFN7O2/c1-7-24(41)38-14-19(6)39(15-18(38)5)29-20-13-21(32)27(25-22(33)9-8-10-23(25)34)36-30(20)40(31(42)37-29)28-17(4)11-12-35-26(28)16(2)3/h7-13,16,18-19H,1,14-15,34H2,2-6H3/t18-,19+/m1/s1",C[C@@H]1CN([C@H](CN1C(=O)C=C)C)C2=NC(=O)N(C3=NC(=C(C=C32)Cl)C4=C(C=CC=C4F)N)C5=C(C=CN=C5C(C)C)C,CC1CN(C(CN1C(=O)C=C)C)C2=NC(=O)N(C3=NC(=C(C=C32)Cl)C4=C(C=CC=C4F)N)C5=C(C=CN=C5C(C)C)C,HBHOIHAXRLHFTR-MOPGFXCFSA-N,"7-(2-amino-6-fluorophenyl)-6-chloro-4-[(2S,5R)-2,5-dimethyl-4-prop-2-enoylpiperazin-1-yl]-1-(4-methyl-2-propan-2-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2-one",589.237,589.237,0,1,0,2,2,0,0,0,0,0,8,2,"",Biological Test Results|Classification|Patents|Biological Test Results: Active|Biological Test Results: Micromolar,5,1806466,20190720,"AbaChemScene|BindingDB|BLD Pharm|Debye Scientific Co., Ltd|Google Patents|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
137796984,KRAS G12C inhibitor 11,KRAS G12C inhibitor 11,551.700,C32H37N7O2,88.800,969.000,4.100,41,0,8,7,"InChI=1S/C32H37N7O2/c1-3-30(40)39-19-18-38(20-24(39)13-15-33)31-27-14-17-37(29-12-6-9-23-8-4-5-11-26(23)29)21-28(27)34-32(35-31)41-22-25-10-7-16-36(25)2/h3-6,8-9,11-12,24-25H,1,7,10,13-14,16-22H2,2H3/t24-,25-/m1/s1",CN1CCC[C@@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=CC=CC=C54)C(=N2)N6CCN([C@@H](C6)CC#N)C(=O)C=C,CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=CC=CC=C54)C(=N2)N6CCN(C(C6)CC#N)C(=O)C=C,OBKBMFMBHWUYHS-JWQCQUIFSA-N,"2-[(2R)-4-[2-[[(2R)-1-methylpyrrolidin-2-yl]methoxy]-7-naphthalen-1-yl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",551.301,551.301,0,1,0,2,2,0,0,0,0,0,0,0,"","",0,"",20190423,DC Chemicals|Starshine Chemical,Chemical Vendors,""
137297882,KRAS G12C inhibitor 47,KRAS G12C inhibitor 47|CHEMBL4517656|2253119-24-1|SCHEMBL20296493|BDBM50514377|DA-64776|PD168338|HY-146537|CS-0437236,547.000,C30H28ClFN4O3,76.400,955.000,5.400,39,1,4,5,"InChI=1S/C30H28ClFN4O3/c1-4-27(38)34-12-14-35(15-13-34)29-21-16-22(31)20(28-23(32)9-7-11-26(28)37)17-25(21)36(30(39)33-29)24-10-6-5-8-19(24)18(2)3/h4-11,16-18,37H,1,12-15H2,2-3H3",CC(C)C1=CC=CC=C1N2C3=CC(=C(C=C3C(=NC2=O)N4CCN(CC4)C(=O)C=C)Cl)C5=C(C=CC=C5F)O,CC(C)C1=CC=CC=C1N2C3=CC(=C(C=C3C(=NC2=O)N4CCN(CC4)C(=O)C=C)Cl)C5=C(C=CC=C5F)O,AFCLJUXYULJJII-UHFFFAOYSA-N,6-chloro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-propan-2-ylphenyl)-4-(4-prop-2-enoylpiperazin-1-yl)quinazolin-2-one,546.183,546.183,0,1,0,0,0,0,0,0,0,0,26,3,"",Biological Test Results|Classification|Patents|Biological Test Results: Active|Biological Test Results: Micromolar,5,1559566|1559567|1559568|1559569|1559570|1559571|1559572|1559573|1559574|1559575|1559576|1559577|1559578|1559579,20190126,"AbaChemScene|BindingDB|ChEMBL|Debye Scientific Co., Ltd|Google Patents|MedChemexpress MCE|MolGenie|PATENTSCOPE (WIPO)|Probes & Drugs portal|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
137278711,Sotorasib,"Sotorasib|AMG-510|2296729-00-3|AMG510|Lumakras|AMG 510|2252403-56-6|AMG-510 racemate|Kras G12C inhibitor 9|sotorasibum|Kras mutant-targeting AMG 510|4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one|2B2VM6UC8G|Sotorasib [INN]|Sotorasib [USAN]|UNII-2B2VM6UC8G|CHEMBL4535757|CHEBI:178199|2296729-00-3 (racemate)|6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one|(1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one|2296729-66-1|6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one|(1R)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one|(1RA)-6-FLUORO-7-(2-FLUORO-6-HYDROXYPHENYL)-4-((2S)-2-METHYL-4-(1-OXOPROP-2-EN-1-YL)PIPERAZIN-1-YL)-1-(4-METHYL-2-(PROPAN-2-YL)PYRIDIN-3-YL)PYRIDO(2,3-D)PYRIMIDIN-2(1H)-ONE|(1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one|6-FLUORO-7-(2-FLUORO-6-HYDROXYPHENYL)-(1M)-1-(4-METHYL-2-(PROPAN-2-YL)PYRIDIN-3-YL)-4-((2S)-2-METHYL-4-(PROP-2-ENOYL)PIPERAZIN-1-YL)PYRIDO(2,3-D)PYRIMIDIN-2(1H)-ONE|PYRIDO(2,3-D)PYRIMIDIN-2(1H)-ONE, 6-FLUORO-7-(2-FLUORO-6-HYDROXYPHENYL)-1-(4-METHYL-2-(1-METHYLETHYL)-3-PYRIDINYL)-4-((2S)-2-METHYL-4-(1-OXO-2-PROPEN-1-YL)-1-PIPERAZINYL)-, (1R)-|AMG510 racemate|compound (R)-38 (PMID: 31820981)|compound (R)-38 [PMID: 31820981]|Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-|SOTORASIB RACEMATE|Lumykras|Sotorasib isomer|6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)-4-[(2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one|6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one|6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-one|AMG 510 racemate|AMG-510(racemate)|SOTORASIB [JAN]|AMG-510(Sotorasib)|Sotorasib [USAN:INN]|SOTORASIB [WHO-DD]|SOTORASIB [ORANGE BOOK]|SCHEMBL20560375|GTPL10678|C30H30F2N6O3|AMG 510 pound>>AMG-510|DTXSID001099260|GLXC-25372|6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl]-1H,2H-pyrido[2,3-d]pyrimidin-2-one|BCP30452|BCP33368|EX-A3538|BDBM50514402|NSC818433|WHO 11370|AKOS037649138|DB15569|NSC-818433|AC-35168|BA172505|BA172506|BS-16684|HY-114277|CS-0081316|D70074|D77975|AMG510 ; AMG 510; AMG-510; AMG510|6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(2-propanyl)-3-pyridinyl]-4-[(2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl]pyrido[2,3-d]pyrimidin-2(1H)-one",560.600,C30H30F2N6O3,102.000,1030.000,4.000,41,1,7,5,"InChI=1S/C30H30F2N6O3/c1-6-23(40)36-12-13-37(18(5)15-36)28-19-14-21(32)26(24-20(31)8-7-9-22(24)39)34-29(19)38(30(41)35-28)27-17(4)10-11-33-25(27)16(2)3/h6-11,14,16,18,39H,1,12-13,15H2,2-5H3/t18-/m0/s1",C[C@H]1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)O)C5=C(C=CN=C5C(C)C)C)C(=O)C=C,CC1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)O)C5=C(C=CN=C5C(C)C)C)C(=O)C=C,NXQKSXLFSAEQCZ-SFHVURJKSA-N,"6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one",560.235,560.235,0,1,0,1,1,0,0,0,0,146,72,26,"",Biological Test Results|Interactions and Pathways|Chemical and Physical Properties|Classification|Drug and Medication Information|Literature|Patents|Pharmacology and Biochemistry|Safety and Hazards|Toxicity|Use and Manufacturing|Associated Disorders and Diseases|Biological Test Results: Active|Biological Test Results: Micromolar|Biological Test Results: Nanomolar,15,1|3|5|7|9|13|15|19|21|23|25|29|31|33|35|37|39|41|43|45|47|49|53|55|59|65|67|71|73|77|79|81|83|85|89|91|93|95|97|99|101|103|105|107|109|113|115|119|121|123|125|129|131|133|137|139|141|143|145|1559567|1559568|1559569|1559570|1559571|1559572|1559573|1559574|1559575|1559576|1559577|1559578|1559579|1559582|1559583|1559584|1559585|1559586|1559587|1559588|1559589|1559590|1559591|1559592|1559593|1559594|1559595|1559596|1559597|1559599|1559600|1559601|1559602|1559603|1559604|1559605|1559606|1652156|1697072|1697073|1729513|1729514|1729515|1729516|1729517|1729518|1729519|1729520|1729521|1729522|1729523|1729524|1729525|1729526|1769392|1769393|1769394|1769395|1769396|1769397|1769398|1769399|1769400|1769401|1777598|1777599|1777600|1806575|1889606|1889607|1889608|1901007|1901008|1901009|1901010|1918456|1918457|1918458|1918459|1918460|1918470|1937510|1937511|1937523|1939177,20190126,"001Chemical|10X CHEM|A2B Chem|AA BLOCKS|Aaron Chemicals LLC|AbaChemScene|AbovChem LLC|AEchem Scientific Corp., USA|AKos Consulting & Solutions|Amadis Chemical|Ambeed|Angel Pharmatech Ltd.|Apexmol|AppChem|AstaTech, Inc.|AvaChem Scientific|Axon Medchem|BenchChem|BindingDB|BioChemPartner|Biosynce Pharmatech|Biosynth|BLD Pharm|BOC Sciences|ChEBI|Chem-Space.com Database|ChEMBL|ChemIDplus|ChemShuttle|Combi-Blocks|Comparative Toxicogenomics Database (CTD)|CymitQuimica|Davey Lab, Department of Microbiology, NEIDL, Boston University|DC Chemicals|DrugBank|DTP/NCI|eNovation Chemicals|EPA DSSTox|Excenen Pharmatech|FDA Global Substance Registration System (GSRS)|Glixx Labs Inc|Google Patents|Hangzhou APIChem Technology|Human Metabolome Database (HMDB)|InvivoChem|IUPHAR/BPS Guide to PHARMACOLOGY|J&H Chemical Co.,ltd|Key Organics/BIONET|Lan Pharmatech|Mcule|MedChemexpress MCE|Molecule Market|MolGenie|MolPort|Nature Chemical Biology|PATENTSCOPE (WIPO)|Probes & Drugs portal|PubChem Reference Collection|Smolecule|Starshine Chemical|SureChEMBL|TargetMol|THE BioTek|Thieme Chemistry|Wikidata|Win-Win Chemical",Chemical Vendors|Curation Efforts|Governmental Organizations|Journal Publishers|Legacy Depositors|Research and Development|Subscription Services,"C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1902 - Ras Inhibitor|C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor|D000970 - Antineoplastic Agents > D000074322 - Antineoplastic Agents, Immunological > D000082082 - Immune Checkpoint Inhibitors|L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents"
134326383,KRas G12C inhibitor 4,"KRas G12C inhibitor 4|2206736-07-2|2-Piperazineacetonitrile, 4-[7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-[2-(1-piperidinyl)ethoxy]pyrido[3,4-d]pyrimidin-4-yl]-1-(1-oxo-2-propen-1-yl)-, (2S)-|SCHEMBL19948449|DTXSID701099716|AKOS040733549|DA-54673|HY-112494|CS-0046139|(2S)-4-[7-(8-Chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-[2-(1-piperidinyl)ethoxy]pyrido[3,4-d]pyrimidin-4-yl]-1-(1-oxo-2-propen-1-yl)-2-piperazineacetonitrile|2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-(2-piperidin-1-ylethoxy)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",600.200,C33H38ClN7O2,88.800,1000.000,5.000,43,0,8,8,"InChI=1S/C33H38ClN7O2/c1-2-30(42)41-19-18-40(22-25(41)12-14-35)32-26-13-17-39(29-11-7-9-24-8-6-10-27(34)31(24)29)23-28(26)36-33(37-32)43-21-20-38-15-4-3-5-16-38/h2,6-11,25H,1,3-5,12-13,15-23H2/t25-/m0/s1",C=CC(=O)N1CCN(C[C@@H]1CC#N)C2=NC(=NC3=C2CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)OCCN6CCCCC6,C=CC(=O)N1CCN(CC1CC#N)C2=NC(=NC3=C2CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)OCCN6CCCCC6,XCJKUQVOWJDAQL-VWLOTQADSA-N,"2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-(2-piperidin-1-ylethoxy)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",599.278,599.278,0,1,0,1,1,0,0,0,0,0,13,6,"",Patents,1,"",20180623,"10X CHEM|A2B Chem|AA BLOCKS|AbaChemScene|AKos Consulting & Solutions|BOC Sciences|CymitQuimica|Debye Scientific Co., Ltd|EPA DSSTox|Google Patents|InvivoChem|Mcule|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
134325731,KRas G12C inhibitor 3,"KRas G12C inhibitor 3|2206735-75-1|CHEMBL4648852|SCHEMBL19947721|BDBM50539761|AKOS040733548|DA-74791|HY-112493|CS-0046138|2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",586.100,C32H36ClN7O2,88.800,1010.000,4.700,42,0,8,7,"InChI=1S/C32H36ClN7O2/c1-3-29(41)40-18-17-39(19-23(40)12-14-34)31-25-13-16-38(28-11-5-8-22-7-4-10-26(33)30(22)28)20-27(25)35-32(36-31)42-21-24-9-6-15-37(24)2/h3-5,7-8,10-11,23-24H,1,6,9,12-13,15-21H2,2H3/t23-,24-/m0/s1",CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C=C,CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C=C,IYDWXYZUEBUWCQ-ZEQRLZLVSA-N,"2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",585.262,585.262,0,1,0,2,2,0,0,0,0,0,19,8,"",Biological Test Results|Classification|Patents|Biological Test Results: Active|Biological Test Results: Micromolar|Biological Test Results: Nanomolar,6,1652101|1652112|1652113|1652114|1652117|1652126|1652127|1652128|1652129|1652130|1652131|1652132|1652133|1652137|1652138|1652139|1652140|1652141|1652142|1652143|1652144|1652145|1652146|1652147,20180623,"AbaChemScene|AKos Consulting & Solutions|BindingDB|BOC Sciences|ChEMBL|CymitQuimica|Debye Scientific Co., Ltd|Google Patents|InvivoChem|Mcule|MedChemexpress MCE|MolGenie|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
134325670,KRas G12C inhibitor 2,"KRas G12C inhibitor 2|2206735-61-5|2-[(2S)-4-[7-(3-hydroxynaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile|SCHEMBL19947651|BCP29475|AKOS040733547|DA-64769|HY-112492|CS-0046137",567.700,C32H37N7O3,109.000,1000.000,3.800,42,1,9,7,"InChI=1S/C32H37N7O3/c1-3-30(41)39-16-15-38(19-23(39)10-12-33)31-27-11-14-37(29-18-25(40)17-22-7-4-5-9-26(22)29)20-28(27)34-32(35-31)42-21-24-8-6-13-36(24)2/h3-5,7,9,17-18,23-24,40H,1,6,8,10-11,13-16,19-21H2,2H3/t23-,24-/m0/s1",CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC(=CC5=CC=CC=C54)O)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C=C,CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC(=CC5=CC=CC=C54)O)C(=N2)N6CCN(C(C6)CC#N)C(=O)C=C,YKGVCHZNLOIACZ-ZEQRLZLVSA-N,"2-[(2S)-4-[7-(3-hydroxynaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",567.296,567.296,0,1,0,2,2,0,0,0,0,0,9,2,"",Patents,1,"",20180623,"AbaChemScene|AKos Consulting & Solutions|BenchChem|BioChemPartner|BOC Sciences|CymitQuimica|Debye Scientific Co., Ltd|EvitaChem|Google Patents|InvivoChem|Mcule|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol|THE BioTek",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
132145654,KRAS-G12C inhibitor 13,KRAS-G12C inhibitor 13|2158296-45-6|SCHEMBL19617582,528.600,C30H36N6O3,85.300,853.000,4.000,39,1,8,6,"InChI=1S/C30H36N6O3/c1-3-28(38)34-13-15-35(16-14-34)29-25-10-12-36(27-18-23(37)17-21-7-4-5-9-24(21)27)19-26(25)31-30(32-29)39-20-22-8-6-11-33(22)2/h3-5,7,9,17-18,22,37H,1,6,8,10-16,19-20H2,2H3/t22-/m1/s1",CN1CCC[C@@H]1COC2=NC3=C(CCN(C3)C4=CC(=CC5=CC=CC=C54)O)C(=N2)N6CCN(CC6)C(=O)C=C,CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC(=CC5=CC=CC=C54)O)C(=N2)N6CCN(CC6)C(=O)C=C,GQSSXKRUKAMOQS-JOCHJYFZSA-N,"1-[4-[7-(3-hydroxynaphthalen-1-yl)-2-[[(2R)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one",528.285,528.285,0,1,0,1,1,0,0,0,0,0,26,7,"",Patents,1,"",20180129,DC Chemicals|Google Patents|PATENTSCOPE (WIPO)|Starshine Chemical|SureChEMBL,Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
132145444,KRAS G12C inhibitor 5,"KRAS G12C inhibitor 5|2158297-63-1|CHEMBL4648671|2-[(2S)-4-[2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-7-naphthalen-1-yl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile|2-((S)-1-Acryloyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile|SCHEMBL19617338|BDBM50539754|AKOS040733550|DA-64765|PD195342|HY-114168|CS-0078097",551.700,C32H37N7O2,88.800,969.000,4.100,41,0,8,7,"InChI=1S/C32H37N7O2/c1-3-30(40)39-19-18-38(20-24(39)13-15-33)31-27-14-17-37(29-12-6-9-23-8-4-5-11-26(23)29)21-28(27)34-32(35-31)41-22-25-10-7-16-36(25)2/h3-6,8-9,11-12,24-25H,1,7,10,13-14,16-22H2,2H3/t24-,25-/m0/s1",CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=CC=CC=C54)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C=C,CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=CC=CC=C54)C(=N2)N6CCN(C(C6)CC#N)C(=O)C=C,OBKBMFMBHWUYHS-DQEYMECFSA-N,"2-[(2S)-4-[2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-7-naphthalen-1-yl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",551.301,551.301,0,1,0,2,2,0,0,0,0,0,37,11,"",Biological Test Results|Classification|Patents|Biological Test Results: Active|Biological Test Results: Micromolar,5,1652101|1652110|1652111|1652120|1652121|1652122|1652123|1652124|1652153,20180129,"AbaChemScene|AKos Consulting & Solutions|BenchChem|BindingDB|BLD Pharm|BOC Sciences|ChEMBL|CymitQuimica|Debye Scientific Co., Ltd|EvitaChem|Google Patents|InvivoChem|Mcule|MedChemexpress MCE|MolGenie|PATENTSCOPE (WIPO)|Probes & Drugs portal|Starshine Chemical|SureChEMBL|TargetMol|THE BioTek",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
132145288,KRas G12C inhibitor 1,"KRas G12C inhibitor 1|2158297-28-8|SCHEMBL19617157|AKOS040733546|DA-54662|HY-112491|CS-0046136|1-[(3S)-4-[7-(3-hydroxynaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-3-methylpiperazin-1-yl]prop-2-en-1-one",542.700,C31H38N6O3,85.300,891.000,4.400,40,1,8,6,"InChI=1S/C31H38N6O3/c1-4-29(39)36-14-15-37(21(2)18-36)30-26-11-13-35(28-17-24(38)16-22-8-5-6-10-25(22)28)19-27(26)32-31(33-30)40-20-23-9-7-12-34(23)3/h4-6,8,10,16-17,21,23,38H,1,7,9,11-15,18-20H2,2-3H3/t21-,23-/m0/s1",C[C@H]1CN(CCN1C2=NC(=NC3=C2CCN(C3)C4=CC(=CC5=CC=CC=C54)O)OC[C@@H]6CCCN6C)C(=O)C=C,CC1CN(CCN1C2=NC(=NC3=C2CCN(C3)C4=CC(=CC5=CC=CC=C54)O)OCC6CCCN6C)C(=O)C=C,LTVKHYYCQYQXDM-GMAHTHKFSA-N,"1-[(3S)-4-[7-(3-hydroxynaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-3-methylpiperazin-1-yl]prop-2-en-1-one",542.301,542.301,0,1,0,2,2,0,0,0,0,0,23,7,"",Patents,1,"",20180129,"AbaChemScene|AKos Consulting & Solutions|BOC Sciences|CymitQuimica|Debye Scientific Co., Ltd|Google Patents|InvivoChem|Mcule|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
118019082,KRAS(G12C) inhibitor 1,KRAS(G12C) inhibitor 1|KRAS(G12C)-IN-1|CHEMBL4570801|SCHEMBL16647122|GLXC-20258|1-(4-(6-Chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one,462.900,C25H20ClFN4O2,69.600,721.000,5.100,33,1,6,3,"InChI=1S/C25H20ClFN4O2/c1-2-21(33)30-7-9-31(10-8-30)25-19-13-20(26)22(23(27)24(19)28-14-29-25)18-12-16(32)11-15-5-3-4-6-17(15)18/h2-6,11-14,32H,1,7-10H2",C=CC(=O)N1CCN(CC1)C2=NC=NC3=C(C(=C(C=C32)Cl)C4=CC(=CC5=CC=CC=C54)O)F,C=CC(=O)N1CCN(CC1)C2=NC=NC3=C(C(=C(C=C32)Cl)C4=CC(=CC5=CC=CC=C54)O)F,JIPIHCUZVBBERR-UHFFFAOYSA-N,1-[4-[6-chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one,462.126,462.126,0,1,0,0,0,0,0,0,0,0,30,8,"",Biological Test Results|Classification|Patents,3,1621758|1621759|1621760|1621761|1621762|1621793|1621794|1621795|1621796|1621797,20160223,ChEMBL|Glixx Labs Inc|Google Patents|IBM|MolGenie|PATENTSCOPE (WIPO)|SureChEMBL,Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
73555129,K-Ras(G12C) inhibitor 12,"K-Ras(G12C) inhibitor 12|1469337-95-8|1-(4-(2-((4-Chloro-2-hydroxy-5-iodophenyl)amino)acetyl)piperazin-1-yl)prop-2-en-1-one|1-(4-(2-(4-chloro-2-hydroxy-5-iodophenylamino)acetyl)piperazin-1-yl)prop-2-en-1-one|VC-7958|CHEMBL4293433|1-(4-(2-(4-Chloro-2-hydroxy-5-iodophenylamino)-acetyl)piperazin-1-yl)prop-2-en-1-one|1-[4-[2-(4-chloro-2-hydroxy-5-iodoanilino)acetyl]piperazin-1-yl]prop-2-en-1-one|2-Propen-1-one, 1-[4-[2-[(4-chloro-2-hydroxy-5-iodophenyl)amino]acetyl]-1-piperazinyl]-|1-(4-{2-[(4-chloro-2-hydroxy-5-iodophenyl)amino]acetyl}piperazin-1-yl)prop-2-en-1-one|K RAS INHIBITOR-12?|K-Ras(G12C)-inhibitor-12|GTPL8020|SCHEMBL15337917|BCP23940|EX-A4192|BDBM50549221|s7331|AKOS024258726|AB90801|CCG-269229|CS-5104|NCGC00386405-01|HY-18707|F85297|MDK-7958; MDK7958; MDK 7958|BRD-K90756851-001-01-1",449.670,C15H17ClIN3O3,72.900,457.000,2.200,23,2,4,4,"InChI=1S/C15H17ClIN3O3/c1-2-14(22)19-3-5-20(6-4-19)15(23)9-18-12-8-11(17)10(16)7-13(12)21/h2,7-8,18,21H,1,3-6,9H2",C=CC(=O)N1CCN(CC1)C(=O)CNC2=CC(=C(C=C2O)Cl)I,C=CC(=O)N1CCN(CC1)C(=O)CNC2=CC(=C(C=C2O)Cl)I,JFIFBWVNHLXJFY-UHFFFAOYSA-N,1-[4-[2-(4-chloro-2-hydroxy-5-iodoanilino)acetyl]piperazin-1-yl]prop-2-en-1-one,449,449,0,1,0,0,0,0,0,0,0,1,44,13,"",Biological Test Results|Classification|Literature|Patents|Biological Test Results: Active|Biological Test Results: Micromolar,6,1296008|1296009|1345084|1346986|1346987|1347055|1347159|1347160|1409598|1424601|1508620|1640020|1645758|1645851|1645870|1645876|1645877|1671188|1671193|1683230|1745853|1749710|1749711|1845191|1845192|1845220|1845221|1845222|1845223|1939182,20140508,"001Chemical|10X CHEM|1st Scientific|A&J Pharmtech CO., LTD.|A2B Chem|AA BLOCKS|Aaron Chemicals LLC|AbaChemScene|AbovChem LLC|Aceschem Inc|Achemtek|Acmec Biochemical|Acorn PharmaTech Product List|Adooq BioScience|AK Scientific, Inc. (AKSCI)|AKos Consulting & Solutions|Amadis Chemical|Ambinter|Angel Pharmatech Ltd.|Angene Chemical|ApexBio Technology|AppChem|AstaTech, Inc.|Aurora Fine Chemicals LLC|BenchChem|BindingDB|BioChemPartner|BioCrick|BOC Sciences|Boerchem|Broad Institute|CAPOT|Center for Chemical Genomics, University of Michigan|Chem-Space.com Database|ChEMBL|Chemieliva Pharmaceutical Co., Ltd|ChemShuttle|Cooke Chemical Co., Ltd|Cyclic PharmaTech|CymitQuimica|Davey Lab, Department of Microbiology, NEIDL, Boston University|DC Chemicals|eMolecules|eNovation Chemicals|Excenen Pharmatech|Google Patents|Hairui Chemical|InvivoChem|Iodochem|IUPHAR/BPS Guide to PHARMACOLOGY|Key Organics/BIONET|King Scientific|LabNetwork, a WuXi AppTec Company|Lan Pharmatech|Matrix Scientific|Mcule|MedChemexpress MCE|MolCore|Molecule Market|MolGenie|MolPort|MuseChem|National Center for Advancing Translational Sciences (NCATS)|PATENTSCOPE (WIPO)|Probes & Drugs portal|RR Scientific|Selleck Chemicals|Sinfoo Biotech|Smolecule|Starshine Chemical|SureChEMBL|Synblock Inc|TargetMol|THE BioTek|Therapeutic Target Database (TTD)|Uchem Meditech|University of Kansas High Throughput Screening Laboratory|Wubei-Biochem|ZINC",Chemical Vendors|Curation Efforts|Governmental Organizations|Legacy Depositors|NIH Initiatives|Research and Development,""
71815954,"N-{1-[(2,4-Dichlorophenoxy)acetyl]piperidin-4-Yl}-4-Sulfanylbutanamide","K-Ras(G12C) inhibitor 6|2060530-16-5|MDK30165|N-(1-(2-(2,4-dichlorophenoxy)acetyl)piperidin-4-yl)-4-mercaptobutanamide|JPV55C3PN4|N-[1-[2-(2,4-Dichlorophenoxy)acetyl]-4-piperidinyl]-4-mercapto-butanamide|MDK-30165|N-{1-[(2,4-Dichlorophenoxy)acetyl]piperidin-4-Yl}-4-Sulfanylbutanamide|N-[1-[2-(2,4-dichlorophenoxy)acetyl]piperidin-4-yl]-4-sulfanylbutanamide|Butanamide, N-[1-[2-(2,4-dichlorophenoxy)acetyl]-4-piperidinyl]-4-mercapto-|N-(1-(2-(2,4-Dichlorophenoxy)acetyl)-4-piperidinyl)-4-mercaptobutanamide|N-[1-[2-(2,4-Dichlorophenoxy)acetyl]-4-piperidinyl]-4-mercaptobutanamide|Butanamide, N-(1-(2-(2,4-dichlorophenoxy)acetyl)-4-piperidinyl)-4-mercapto-|UNII-JPV55C3PN4|CHEMBL4303198|SCHEMBL15337738|DTXSID701143036|HMS3653I14|BCP30805|EX-A6825|s7333|AKOS032945138|CCG-268706|DA-64785|TS-08868|HY-107841|CS-0030721|SW222246-1|BRD-K26305185-001-01-3|BRD-K26305185-001-02-1|MDK30165; MDK-30165; MDK 30165|Q27452607|20G",405.300,C17H22Cl2N2O3S,59.600,448.000,3.100,25,2,4,7,"InChI=1S/C17H22Cl2N2O3S/c18-12-3-4-15(14(19)10-12)24-11-17(23)21-7-5-13(6-8-21)20-16(22)2-1-9-25/h3-4,10,13,25H,1-2,5-9,11H2,(H,20,22)",C1CN(CCC1NC(=O)CCCS)C(=O)COC2=C(C=C(C=C2)Cl)Cl,C1CN(CCC1NC(=O)CCCS)C(=O)COC2=C(C=C(C=C2)Cl)Cl,ZPXCEHMKUTXHRZ-UHFFFAOYSA-N,"N-[1-[2-(2,4-dichlorophenoxy)acetyl]piperidin-4-yl]-4-sulfanylbutanamide",404.073,404.073,0,1,0,0,0,0,0,0,0,1,8,1,"",Biological Test Results|Interactions and Pathways|Classification|Literature|Patents,5,1259398|1259399|1259416|1259421|1259423|1347080|1409598|1508586|1508601|1640020|1645758|1749710|1749711|1918969,20131118,"10X CHEM|A2B Chem|AA BLOCKS|Aaron Chemicals LLC|AbaChemScene|AKos Consulting & Solutions|Aladdin|Amadis Chemical|Angel Pharmatech Ltd.|AOBIOUS INC|ApexBio Technology|AppChem|Ark Pharma Scientific Limited|Aurora Fine Chemicals LLC|BenchChem|BioChemPartner|BLD Pharm|BOC Sciences|Broad Institute|Center for Chemical Genomics, University of Michigan|Chem-Space.com Database|ChEMBL|ChemIDplus|ChemShuttle|Clearsynth|Cooke Chemical Co., Ltd|CSNpharm|CymitQuimica|DC Chemicals|Debye Scientific Co., Ltd|Egon Willighagen, Department of Bioinformatics - BiGCaT, Maastricht University|eMolecules|eNovation Chemicals|EPA DSSTox|Excenen Pharmatech|FDA Global Substance Registration System (GSRS)|Fisher Drug Discovery Resource Center|Google Patents|IBM|ICCB-Longwood Screening Facility, Harvard Medical School|InvivoChem|Key Organics/BIONET|Lan Pharmatech|Mcule|MedChemexpress MCE|Molecule Market|MolGenie|MolPort|NCBI Structure|PATENTSCOPE (WIPO)|Probes & Drugs portal|Protein Data Bank in Europe (PDBe)|Selleck Chemicals|Smolecule|Starshine Chemical|SureChEMBL|TargetMol|THE BioTek|Thomson Pharma|UCSC Chemical Screening Center|University of Kansas High Throughput Screening Laboratory|Wikidata|ZINC",Chemical Vendors|Curation Efforts|Governmental Organizations|Journal Publishers|Legacy Depositors|NIH Initiatives|Research and Development|Subscription Services,""
71761630,K-Ras(G12C) inhibitor 9,K-Ras(G12C) inhibitor 9|1469337-91-4|K-Ras(GI2C) Inhibitor 9|K-RAS inhibitor 9|N-[1-[2-(4-chloro-5-iodo-2-methoxyanilino)acetyl]piperidin-4-yl]ethenesulfonamide|N-[1-[2-[(4-Chloro-5-iodo-2-methoxyphenyl)amino]acetyl]-4-piperidinyl]ethenesulfonamide|K-RAS inhibitor 9?|GTPL8022|CHEMBL4278453|SCHEMBL15337776|HMS3653G14|BCP12230|EX-A7981|AKOS032945137|CCG-269803|NCGC00384194-02|DA-54685|HY-12446|TS-09328|CS-0011376|S7332|SW219243-1|J-008285|N-(1-{2-[(4-chloro-5-iodo-2-methoxyphenyl)amino]acetyl}piperidin-4-yl)ethene-1-sulfonamide|N-(1-{2-[(4-chloro-5-iodo-2-methoxyphenyl)amino]acetyl}piperidin-4-yl)ethenesulfonamide,513.799,C16H21ClIN3O4S,96.100,593.000,2.800,26,2,6,7,"InChI=1S/C16H21ClIN3O4S/c1-3-26(23,24)20-11-4-6-21(7-5-11)16(22)10-19-14-9-13(18)12(17)8-15(14)25-2/h3,8-9,11,19-20H,1,4-7,10H2,2H3",COC1=CC(=C(C=C1NCC(=O)N2CCC(CC2)NS(=O)(=O)C=C)I)Cl,COC1=CC(=C(C=C1NCC(=O)N2CCC(CC2)NS(=O)(=O)C=C)I)Cl,ZGUSBCDCZNBNQT-UHFFFAOYSA-N,N-[1-[2-(4-chloro-5-iodo-2-methoxyanilino)acetyl]piperidin-4-yl]ethenesulfonamide,512.999,512.999,0,1,0,0,0,0,0,0,0,1,14,5,"",Biological Test Results|Classification|Literature|Patents|Biological Test Results: Active,5,1296008|1296009|1345084|1346986|1346987|1347055|1347080|1347159|1347160|1424601|1508586|1508598|1508601|1508620|1645851|1645870|1645876|1645877|1671188|1671193|1745853|1845191|1845192|1845220|1845221|1845222|1845223|1918969|1945148|1945149|1945150|1945151|1945156|1945157|1945158,20131104,"10X CHEM|A2B Chem|AA BLOCKS|Aaron Chemicals LLC|AbaChemScene|AbMole Bioscience|Adooq BioScience|AK Scientific, Inc. (AKSCI)|AKos Consulting & Solutions|Aladdin|Amadis Chemical|Ambeed|Angel Pharmatech Ltd.|AOBIOUS INC|Aurora Fine Chemicals LLC|BenchChem|BioChemPartner|BioCrick|Biosynth|BOC Sciences|Center for Chemical Genomics, University of Michigan|Chem-Space.com Database|ChEMBL|Chemieliva Pharmaceutical Co., Ltd|Clearsynth|Cooke Chemical Co., Ltd|Cure First|CymitQuimica|DC Chemicals|Debye Scientific Co., Ltd|eMolecules|eNovation Chemicals|Excenen Pharmatech|Google Patents|ICCB-Longwood Screening Facility, Harvard Medical School|InvivoChem|IUPHAR/BPS Guide to PHARMACOLOGY|Key Organics/BIONET|LabNetwork, a WuXi AppTec Company|Lan Pharmatech|Mcule|MedChemexpress MCE|Molecule Market|MolGenie|MolPort|MuseChem|National Center for Advancing Translational Sciences (NCATS)|PATENTSCOPE (WIPO)|Probes & Drugs portal|RR Scientific|Selleck Chemicals|Smolecule|Starshine Chemical|SureChEMBL|TargetMol|THE BioTek|Therapeutic Target Database (TTD)|Thomson Pharma|UCSC Chemical Screening Center|University of Kansas High Throughput Screening Laboratory|ZINC",Chemical Vendors|Curation Efforts|Governmental Organizations|Journal Publishers|Legacy Depositors|NIH Initiatives|Research and Development|Subscription Services,""
4025318,KRAS G12C inhibitor 29,"KRAS G12C inhibitor 29|847337-63-7|3-(2-chloro-6-fluorobenzyl)-1-methyl-9-(3-methylphenyl)-6,7,8,9-tetrahydropyrimido[2,1-f]purine-2,4(1H,3H)-dione|3-[(2-chloro-6-fluorophenyl)methyl]-1-methyl-9-(3-methylphenyl)-7,8-dihydro-6H-purino[7,8-a]pyrimidine-2,4-dione|STL004186|AKOS001408232|DA-54669|HY-142478|CS-0372473|Z246074520",453.900,C23H21ClFN5O2,61.700,743.000,4.200,32,0,5,3,"InChI=1S/C23H21ClFN5O2/c1-14-6-3-7-15(12-14)28-10-5-11-29-19-20(26-22(28)29)27(2)23(32)30(21(19)31)13-16-17(24)8-4-9-18(16)25/h3-4,6-9,12H,5,10-11,13H2,1-2H3",CC1=CC(=CC=C1)N2CCCN3C2=NC4=C3C(=O)N(C(=O)N4C)CC5=C(C=CC=C5Cl)F,CC1=CC(=CC=C1)N2CCCN3C2=NC4=C3C(=O)N(C(=O)N4C)CC5=C(C=CC=C5Cl)F,GWEBJSRHSQNRTI-UHFFFAOYSA-N,"3-[(2-chloro-6-fluorophenyl)methyl]-1-methyl-9-(3-methylphenyl)-7,8-dihydro-6H-purino[7,8-a]pyrimidine-2,4-dione",453.137,453.137,0,1,0,0,0,0,0,0,0,0,0,0,"",Classification|Spectral Information,2,"",20050913,"A2B Chem|AbaChemScene|ABI Chem|AKos Consulting & Solutions|Ambinter|Aurora Fine Chemicals LLC|BenchChem|BLD Pharm|Chem-Space.com Database|ChemDB|ChemSpider|Debye Scientific Co., Ltd|DiscoveryGate|Enamine|InvivoChem|LabNetwork, a WuXi AppTec Company|Mcule|MedChemexpress MCE|MolPort|NextBio|TargetMol|TimTec|Vitas-M Laboratory|ZINC",Chemical Vendors|Legacy Depositors|Research and Development|Subscription Services,""
